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ABSTRACT
Obesity is associated with chronic low-grade inflammation and dysregulations in the
endocrinological functions of peripheral tissues, including adipose tissue. It predisposes
the individual to chronic diseases, including cardiovascular diseases and type 2 diabetes
(T2D), but also to other conditions affecting the quality of life, such as age-related
macular degeneration (AMD). Many of the obesity-related conditions exhibit abnormal
angiogenesis as a part of the pathophysiology. Previous studies by our group have
demonstrated that long-term weight reduction can change the gene expression profile of
adipose tissue in overweight individuals with impaired fasting glucose or impaired
glucose tolerance (IGT). One of the most downregulated genes was tenomodulin
(TNMD). TNMD is located in the X-chromosome and has been shown to inhibit
angiogenesis.
   The role of TNMD as a susceptibility gene for obesity- and inflammation-related
traits was investigated by studying the association of single nucleotide polymorphisms
(SNPs) with obesity and indicators of glucose and lipid metabolism in 507 overweight
individuals with IGT who participated in the Finnish Diabetes Prevention Study (DPS),
and in a cross-sectional population-based cohort of middle-aged men (the METSIM
study, n=5298). In addition, the association with proinflammatory markers was studied
in DPS and the association with AMD in a separate sample of 475 non-diabetic
individuals.
Three markers were associated with conversion from IGT to T2D in DPS, but not
with the prevalence of T2D in METSIM. The same genotypes that had elevated risk for
developing T2D were associated with elevated serum concentrations of inflammation
markers in DPS and with higher serum cholesterol concentrations in the obese men of
both study populations. In women, the sequence variation of TNMD was associated with
serum concentrations of proinflammatory factors, central obesity and prevalence of
AMD. The associations with inflammatory mediators were modified by central obesity
and the status of glucose metabolism.
In conclusion, these results suggest that the genetic variation of TNMD might be
related to the risk for components of metabolic syndrome, a constellation of
dyslipidaemia, central obesity, insulin resistance and chronic low-grade inflammation,
especially in the high-risk individuals.
National Library of Medicine Classification: QZ 50, WD 200.5.H8, WK 810, WK 820
Medical Subject Headings: Cholesterol; Diabetes Mellitus, Type 2/genetics;
Dyslipidemias; Finland; Genetic Variation; Genotype; Glucose Intolerance/genetics;
Glucose/metabolism; Insulin Resistance/genetics; Lipid Metabolism; Metabolic
Syndrome X; Middle Aged; Obesity/genetics; Polymorphism, Genetic; Polymorphism,
Single Nucleotide/genetics; Quality of Life; TNMD protein, human; X Chromosome
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1 INTRODUCTION
Obesity, defined as body mass index (BMI) 30 has become a major public health
problem, especially in the developed countries but also in the rapidly-developing
countries. The aetiology of obesity is a complex interplay between environmental,
genetic and behavioural factors even though the fundamental cause is known, i.e. the
imbalance between energy expenditure and intake. The storage of this surplus energy
into adipocytes evokes disturbances in the cellular organization and secretory functions
of adipose tissue, thereby leading to various metabolic abnormalities and chronic low-
grade inflammation.
Excess fat mass, especially in the abdominal region, is one key component of
metabolic syndrome, a cluster of metabolic abnormalities including dyslipidaemia,
insulin resistance, glucose intolerance, hypertension and inflammation. The obesity
epidemic has also resulted in a higher prevalence and the incidence of obesity-related
conditions, including diseases which can dramatically shorten the life span, for
example, cardiovascular diseases, certain types of cancer and type 2 diabetes (T2D). In
addition, obesity predisposes to other conditions with tremendous effect on the quality
of life, such as osteoarthritis and age-related macular degeneration (AMD).
In addition to the inflammatory mediators, adipose tissue produces and secretes
molecules that regulate angiogenesis. Interestingly, many of the related conditions,
including cardiovascular diseases, AMD and microvascular complications of T2D
exhibit vascular dysfunction and dysregulation as an essential part of their
pathophysiology.
It is also known that alterations in body weight and fat mass influence the gene
expression profile of adipose tissue. In a previous study, tenomodulin (TNMD),  a
putative angiogenesis inhibitor, was one of the most extensively downregulated genes
during long-term weight reduction in overweight individuals with impaired fasting
glucose (IFG) or impaired glucose tolerance (IGT). This finding provided the impetus to
investigate whether TNMD could  be  a  susceptibility  gene  for  obesity  and  its  related
conditions.
The purpose of this work was to investigate the association of common sequence
variation in the TNMD gene with obesity- and inflammation-related phenotypes,
including 1) anthropometric measurements, 2) glucose metabolism and incidence or
16
prevalence of type 2 diabetes, 3) low-grade inflammation indicated by serum levels of
systemic immune mediators, 4) serum levels of lipids and lipoproteins and 5)
prevalence of age-related macular degeneration.
17
2 REVIEW OF THE LITERATURE
2.1 Obesity
Obesity is characterized by the excess accumulation of adipose tissue, often to an extent
that endangers an individual's health. The adipose tissue mass can be measured by
various methods such as bioelectrical impedance, underwater weighing, total body water
or potassium content or by different imaging methods (1-3). Apart from bioelectrical
impedance, these techniques are rather cumbersome and expensive and thus different
surrogate measures are applied in the clinical settings. The most common surrogate
marker for body fat content is BMI, calculated as weight in kilograms divided by height
in meters squared. According to World Health Organization (WHO) guidelines (4),
determined on the basis of mortality statistics from the United States (5), overweight is
defined as BMI>25 kg/m2 and obesity as BMI 30 kg/m2. Since abdominal obesity is
specifically associated with the metabolic risk factors (6), the measures of central
obesity, such as waist circumference or waist to hip-ratio (WHR) are also feasible in the
estimation of abdominal and general fat mass (1,2). The cut-offs for central obesity in
European populations, based on the definitions of metabolic syndrome according to
WHO (7) and the European Group for the Study of Insulin Resistance (EGIR) (8) are
waist circumference 80 cm in women and 94 cm in men (8) and/or WHR 0.85 in
women and 0.9 in men (7).
In the population-based FIN-D2D survey, which was conducted in Finland between
October 2004 and January 2005,  24% of men and 29% of women were classified as
obese, 50% of men and 38% of women were overweight and 69% of men and 76% of
women fulfilled the criteria for central obesity (9). These numbers are in line with
estimations from many other developed countries, as for example in the United States
where 31.1% of men and 33.1% of women were obese in 2004 (10) while 17.8% of
Australian men and 15.1% of women were obese and 61.9% of men and 45% of women
were overweight in 2006 (11). In the majority of European countries, the prevalence of
obesity increased by up to 40 % between 1989 and 1999 (2).
2.1.1 Lifestyle-related risk factors of obesity
The high and constantly increasing prevalence of obesity is due to two major
environmental factors: changes in food intake and physical activity (6). During the last
18
decades, the energy intake has increased due to larger portion sizes and higher energy
density of foods (12-15). In combination with decreased physical activity (15,16), these
plentiful supplies of food in the developed countries have resulted in the mushrooming
of obesity, which represents a major challenge for modern society. Accordingly, a multi-
faceted approach including urban planning, lifestyle education and changes in the food
policy is needed to overcome these factors (17).
2.1.2 Genetic risk factors of obesity
The obesity epidemic can be considered as having strong genetic determinants since 30-
80% of the variation in body fat has been attributed to genetic factors (18-20). The
inheritance  of  abdominal  obesity  is  also  high,  e.g  in  a  sample  of  post-menopausal
women genetic factors were considered to explain 60% of the variance in abdominal fat
(21). Many of the characterized genetic risk factors are related to regulation of food
intake and metabolic pathways (22), but susceptibility genes with unknown functions
have also been identified (23-27).
The genetic risk factors can be divided into variants that cause mono- or polygenic
obesity. The human obesity gene map published in 2005 (22), lists a total of 11 genes in
which mutations cause monogenic obesity, such as the leptin (28), leptin receptor (29)
and melanocortin 4 receptor genes (30). However, since these mutations with high
penetrance and a large effect are rare, they are not feasible markers at the population
level.
The recent technological advancements which have made genome-wide scans easier
and more affordable have facilitated the identification of common variants. For
example,  the  association  of  the  genes  encoding  fat  mass  and  obesity-  associated  gene
(FTO) (23-26), catenin, -like 1 (CTNNBL1) and phosphofructokinase platelet type
(PFKP) (25,27) with obesity have been replicated in more than one large study
population, but as these variants have low penetrance and a relatively small effect size,
they are currently not useful predictors for the propensity to obesity at the general
population level. For example, the individuals who harbour the risk genotype (AA) of
the marker rs9939609 within the gene encoding FTO weigh approximately 3 kg more
than individuals without the risk allele (genotype rs9939609-TT) (24). The effect of the
marker rs6013029, which is located in the CTNNBL1 is stronger, since the individuals
with the rs6013029-TT genotype have 2.67 units higher BMI and 5.96 kg higher fat
mass than individuals with the rs6013029-GG genotype (27).
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In addition to these genes and variants in which the associations have been
replicated, there are a number of genes with conflicting results, such as peroxisome
proliferator-activated receptor- (PPAR-)  (31,32).  The failure in replication can result
from differences in the study populations, heterogeneity in the disease aetiology or from
dissimilar ascertainment schemes, for example recruiting subjects with mild or severe
obesity (33). The replication studies might also have been conducted in different ethnic
groups with allele frequencies that differ from those observed in the original study
population (34). Inadequate sample sizes, failure to attribute positive results to chance
in the initial studies (35) or environmental differences can also account for the
heterogeneity between different genetic association studies.
2.2 Obesity-related co-morbidities
In obese individuals, the mass of adipose tissue, a major endocrine organ with various
para- and autocrine functions, is increased. Therefore it is not surprising that obesity is
the main risk factor for a number of metabolic abnormalities (1,2,4). Almost all, 90%,
of individuals who have type 2 diabetes (T2D) are overweight (36). Furthermore,
obesity increases the risk for various other conditions, many of which are associated
with vascular dysfunction and disturbances in neovascularization, such as
cardiovascular disease, certain types of cancer and age-related macular degeneration
(1,2,4).  In  addition,  central  obesity  is  a  key  component  of  the  metabolic  syndrome,  a
constellation of metabolic abnormalities and cardiovascular disease risk factors (6,7,37).
2.2.1 Metabolic syndrome
The concept of the  metabolic syndrome has existed for at least 80 years and was
originally defined as the clustering of hypertension, hyperglycaemia and gout but in
1940´s upper body adiposity was also included in the definition (38). In 1988, Reaven
underlined the importance of insulin resistance in his description of the metabolic
syndrome, or syndrome X, a combination of hyperinsulinaemia, glucose intolerance,
hypertension and dyslipidaemia (39). It is notable that central obesity was not included
in this definition.
Nowadays, the definition of metabolic syndrome as a constellation of metabolic
abnormalities has been widely accepted, but the exact diagnostic criteria were defined
for the first time in 1998 when WHO (7), EGIR (8) and the National Cholesterol
20
Education Program’s Adult Treatment Panel III (NCEP: ATP III) (40) formulated their
consensus statements. Subsequently, various other criteria, including those of
International Diabetes Federation (IDF) (41), American Heart Association/National
Heart, Lung and Blood Institute (42) and Association of American Clinical
Endocrinologists (43) were introduced (Table 1).
All of these six definitions include central obesity, hyperglycaemia, hypertension
and dyslipidaemia as indicated by elevated serum triglycerides and/or decreased high-
density lipoprotein (HDL) concentration, but the cut-off points and the amount of
criteria that need to be fulfilled vary to some extent. This discrepancy between criteria
naturally affects the absolute prevalence estimates of the metabolic syndrome, but
regardless of the applied criteria, the explosion in the numbers of individuals with these
metabolic abnormalities is a growing burden to health care systems (41).
Visceral, rather than the subcutaneous fat depot is generally believed to be the main
culprit of the metabolic syndrome (44), as it is considered to be more metabolically
active and it is able to deliver endocrinal factors to the portal veins and can thus directly
impact on the liver (45). The amount of the subcutaneous depot can exceed that of
visceral by 3-4 times (46), and thus it should not be ignored. However, a recent study in
the Framingham Heart Study population showed that while abdominal adiposity in
general was related to a higher risk of metabolic and cardiovascular disease,
subcutaneous abdominal fat was not associated with a linear increase in the prevalence
of components of metabolic syndrome, including low HDL, high triglycerides and
hypertension among  obese individuals (47).
It has been suggested that especially the visceral adipose depot has a central role in
the development and maintenance of a proinflammatory state, as reflected in the
elevated serum C-reactive protein (CRP) concentration and prothrombotic state, evident
as increased plasma concentrations of plasminogen activator inhibitor and fibrinogen
(44,45). These two states are also characteristics of the metabolic syndrome, but they
are not included in the diagnostic criteria (7,8,40-42). Both features are likely caused by
multiple mechanisms, but there is a growing body of evidence suggesting that these
states are metabolically interconnected and result from the dysregulation in the
expanding adipose tissue (6,48-51).
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2.2.1.1 Genetic risk factors for metabolic syndrome
In addition to obesity, many of the other individual components of metabolic syndrome
have genetic background, although they also are strongly influenced by environmental
factors. Insulin resistance clusters in families, since 45% of first-degree relatives of
patients with T2D are insulin resistant on the basis of euglycaemic insulin clamp
technique, compared with 20% of people without a family history of T2D (52,53). The
heritability estimates for other components of the metabolic syndrome range from 0.3 to
0.92 (Table 2). Findings from twin and family studies suggest that in addition to the
individual components, the clustering of metabolic syndrome factors is also heritable
(54-56).
Table 2. The heritability estimates for the components of metabolic syndrome.
Component Heritability Reference
Glycaemic disturbances 0.57-0.92 (55)
Blood pressure 0.4-0.5 (57)
Dyslipidaemia 0.3 (55)
Albumin excretion 0.3 (58)
Abdominal visceral fat 0.42-0.6 (21,59)
Body fat 0.3-0.8 (18-20)
2.2.2 Type 2 Diabetes
T2D is a heterogeneous group of diseases, characterized by hyperglycaemia resulting
from defects in insulin secretion and insulin responses (60,61). Prolonged
hyperglycaemia is associated with dysfunction, damage to and even failure of different
tissues and organ systems, including eyes, kidneys, heart, nerves and blood vessels
(61,62). The related conditions include microvascular complications such as diabetic
nephropathy, retinopathy and neuropathy and macrovascular complications, including
cardiovascular, cerebrovascular and peripheral vascular diseases (62,63). The WHO
1985 and 1999 diagnostic criteria for impaired glucose regulation which are based on
the determination of fasting plasma glucose concentration (FPG) and 2-hour venous
plasma glucose concentration (2h-PG) in an oral glucose tolerance test (OGTT) are
presented in Table 3.
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Table 3. The WHO 1985 and 1999 diagnostic criteria of impaired glucose regulation (60,62).
1985 criteria 1999 criteria
FPG (mmol/l) 2h-PG(mmol/l)
FPG
(mmol/l)
2h-PG
(mmol/l)
Normoglycaemia <7.8 implied <7.8 implied <6.1 <7.8 implied
IFG Not defined 6.1, <7 <7.8
IGT <7.8 7.8, <11.1 6.1, <7 7.8, <11.1
T2D 7.8 11.1 7.0 11.1
The category of IFG was introduced in the WHO criteria in 1999, with the main
aim of creating a fasting category which would be analogous to IGT. The suitable lower
cut-off for this glucose tolerance class has been disputed. In 2003, the American
Diabetes Association recommended that it should be lowered to 5.6 mmol/l (64), while
the cut-off proposed by WHO 1999 criteria is 6.1 mmol/l (62).  The rationale was to
identify similar proportions of the population with IFG and IGT, and to produce
equivalent  predictive  power  for  progression  to  diabetes  from  the  IGT  and  IFG
categories (64). The European Diabetes Epidemiology Group estimated that the change
in cut-off would have resulted in two-to five-fold increase in the prevalence of IFG
across the world and since the total benefits or costs of designating individual as at risk
for diabetes were not known, they did not recommend the lower threshold (65).
In parallel with the obesity epidemic, the prevalence of T2D has increased during
the last decades (66). According to the FIN-2D2 survey of 2004-2005, 16 % of Finnish
men and 11 % of women had T2D, while 42% of men and 33 % of women had
abnormal glucose regulation (IFG, IGT or T2D) (9). The global prevalence
approximation of T2D in 2000 was 2.8%, which is estimated to increase to 4.4% in
2030 (67). The highest increases in T2D prevalence are predicted to take place in the
Middle Eastern Crescent (163%), Sub-Saharan Africa (161%), Latin America and the
Caribbean and in Asia (regionwise estimates ranging from 104 to 151%).
2.2.2.1 Environmental risk factors of type 2 diabetes
Obesity, especially in the abdominal region, increases the risk of T2D and accordingly,
the main environmental risk factors of T2D are related to lifestyle (68,69). Several
studies have indicated that metabolic syndrome predicts future diabetes (70,71).
However, as hyperglycaemia and insulin resistance are the key components of EGIR´s
(8) and WHO´s (7) diagnostic criteria for metabolic syndrome and they also belong to
the other definitions of metabolic syndrome (40-43), this is not unexpected. Other non-
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genetic risk factors include age (69), low physical activity (68,69) and intrauterine
exposure to hyperglycaemia and malnutrition (72,73). The nutritional risk factors
include a high fat diet rich in saturated fatty acids and low intake of dietary fibre (74). In
addition, consumption of foods with a high glycaemic index has been linked to an
increased risk of T2D (75-79), but these findings are controversial (80,81).
The successfulness of lifestyle intervention on preventing the onset of T2D in
high-risk individuals has been demonstrated in different study populations, including
Finnish (82,83), Swedish (84), Chinese (85) and American (86) individuals. In the
Finnish Diabetes Study (DPS) (83), 522 middle-aged overweight individuals with IGT
were randomized into two groups. The intervention group received intensive,
individualized diet and exercise counselling while the control group received general
information about diet and exercise instructions. During the actual study period which
had a median follow-up time of four years, the risk of T2D was reduced by 58% in the
intervention group (82). This reduction was directly associated with lifestyle changes
(82) and the reduction in the incidence of T2D was sustained when the participants were
further followed up for a median of three years (87). In the 6-year Malmö feasibility
study which examined Swedish middle-aged men, a 50% risk reduction in the incidence
of  T2D  was  observed  among  those  who  volunteered  to  participate  in  the  diet  and
exercise intervention in comparison to those who refused to participate (84). The
Chinese Da Qing- Study investigated the efficacy of diet, exercise or their combination
in reducing the incidence of T2D during six years of follow-up (85). All three
approaches were almost equally effective, since the incidence of T2D was 67.7% in the
control group, 41.1% in the exercise group, 43.8% in the diet group and 46% in the
group that combined diet and exercise. The Diabetes Prevention Program, conducted in
the US, compared the efficacy of lifestyle modification and oral administration of
metformin in preventing or delaying the onset of T2D among high-risk individuals (86).
Similar to the DPS, the participants were overweight and had IGT. Metformin treatment
reduced the risk of T2D by 31%, while the risk reduction achieved by lifestyle
modification was identical to that observed in the DPS (58%).
2.2.2.2 Genetic risk factors for type 2 diabetes
The genetic determinants of T2D are indicated by familial clustering (52,53), marked
differences in the prevalence among various ethnic and racial groups (88-91) and
different concordance rates between monozygotic and dizygotic twins (55,92). The
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general pattern of inheritance of T2D in families is consistent with it being a complex,
multifactorial disease with polygenic background (93,94). Accordingly, only a few
monogenic forms have been described and they are estimated to account for only
approximately 5% of the total T2D in most populations (95). The genetic risk factors
are estimated to account for 40-85% of total disease susceptibility (96).
Many genes with a modest effect size have been identified with the candidate gene
approach (93,94,97,98), the best-established being PPAR- (99-102) and potassium
inwardly-rectifying channel, subfamily J, member 11 (KCNJ11) (26,101,103-107). The
associations of these two genes have been replicated in the genome-wide scans
(25,26,108), which have also revealed many new, promising candidates, including the
genes encoding transcription factor 7-like 2 (TCF7L2), FTO, homeobox
hematopoietically expressed (HHEX) and cyclin-dependent kinase inhibitor-2A/B
(CDKN-2A/B). The most consistent associations have been observed with TCF7L2
(26,107,109-111). A meta-analysis of 29195 controls and 17202 cases provided a
pooled odds ratio (OR) of 1.46 for the rs7903146-TT genotype (112). The variants of
TCF7L2 increase the risk of T2D independently of BMI (26,107,113) and have been
linked to impaired insulin secretion (113). In most of the studies, the variants of FTO
have been shown to increase the risk of T2D by affecting the body size (24-26,114), but
in a German cohort a BMI-independent effect was observed (107). The OR for the risk
genotype rs9939609-AA  ranges between 1.22-1.27 (24,26,114).  The associations of
HHEX and CDKN-2A/B have been replicated in populations of Asian and Caucasian
origin, with the ORs for risk genotypes being between 1.1-1.4 (26,107,108,114). In
addition, in a recent meta-analysis of three genome-wide scans for T2D, six new loci
were identified, including juxtaposed with another zinc finger gene 1 (JAZF1), thyroid
adenoma associated gene (THADA)  and  a  disintegrin  and  metalloproteinase  with
thrombospondin type 1 motif, 9 (ADAMTS9) and the intergenic regions between the
genes encoding  cell division cycle 123 homolog (S. cerevisiae)  (CDC123) and
calcium/calmodulin-dependent protein kinase 1D (CAMK1D), tetraspanin 8 (TSPAN8)
and leucine-rich repeat-containing G protein coupled receptor 5 (LGR5), and between
Notch homolog 2 (Drosophila)  (NOTCH2) and a disintegrin and metalloproteinase
domain 30 (ADAM30) (115). The OR for the individual risk alleles range between 1.05
and 1.11.
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2.2.3 Age-related macular degeneration
Age-related macular degeneration is a progressive, chronic disease with a multifactorial
background (116). According to the prevalence estimates from WHO, it is the most
common cause of blindness in the developed countries (117) as it has been estimated to
be  the  cause  of  half  of  all  cases  of  blindness  in  Western  populations  over  65  years  of
age (118). AMD is associated with aging and it gradually destroys sharp, central vision
(116) as degenerative tissue alterations occur at the interface between the neural retina
and underlying choroid (119,120).
AMD can be divided into atrophic (dry) and exudative (wet) subforms, with the
former being more common and accounting for approximately 80% of AMD cases
(121). Drusens are one of the most common early manifestations, followed by
geographic atrophy in the atrophic form of AMD, or by neovascularization in the
exudative form. The atrophic form involves modifications in pigment distribution, loss
of retinal pigment epithelium cells and photoreceptors, and reduced retinal function due
to an overall atrophy of the cells (116,122). Together these changes gradually blur the
central vision. The hallmark feature of the exudative form is the proliferation of
abnormal, fragile choroidal blood vessels, which enter into the subretinal space thereby
resulting into retinal detachment, hemorrhages, exudates and glial proliferation with
scarring (116,122).
Although the exact pathogenic process is still unclear, the roles of oxidative stress
(119) and dysregulated angiogenesis (123) are now well established. The expression
levels of inhibitors and stimulators of neovascularization are known to be altered during
the development of AMD (123-125). For example, vascular endothelial growth factor
(VEGF), is strongly involved in choroidal neovascularization (125) and accordingly, the
VEGF-blocking compounds are emerging as the most successful treatment for
exudative AMD (126-129).
2.2.3.1 Environmental risk factors for age-related macular degeneration
In addition to age (116), gender and smoking, obesity and its related conditions such as
hypertension and hypercholesterolemia predispose to AMD (130-135). Interestingly,
many of these environmental risk factors, such as smoking status, dietary habits,
obesity, high serum cholesterol, gender and age are associated with the amount of
macular pigment (136,137), which seems to be a protective factor from photo-oxidative
damage (138).
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2.2.3.2  Genetic risk factors for age-related macular degeneration
Family  and  twin  studies  have  underlined  the  presence  of  genetic  risk  factors.  First-
degree relatives of patients with AMD have a higher risk of AMD than those without a
family history (139,140). They are also affected at a younger age and have an increased
lifetime risk of late AMD (141,142). Accordingly, the heritability estimates are
relatively high, 0.46-0.71 for AMD (139), 0.67-0.85 for macular pigment density (143)
and 0.63 for the amount of small hard drusens (144).
The importance of genetic risk factors, specifically of those related to the
complement system, has been demonstrated with genome-wide scans and the candidate
gene approach. Recently, an association between the rs1061170 (also known as Y402H)
of the complement factor H gene CFH and AMD was revealed in several different
populations (145-151) with ORs generally ranging between 2.45 and 5.57 for the
homozygotes of the risk allele rs1061170-C. An association between the
LOC387715/HTRA1 locus and AMD in both Caucasian and Japanese and Chinese
populations has been documented (152-159). The odds ratios range between 1.69 and
2.61 for heterozygotes and between 2.20 and 9.90 for homozygotes of the risk
genotypes. A common polymorphism (rs2230199) in the complement component 3
gene  (C3) has also been associated with AMD (160,161). Other suggested candidates
include genes related to fatty acid metabolism, such as apolipoprotein E (162-164),
ATP-binding cassette, subfamily A, member 4 (ABCA4) (165,166) and elongation of
very long chain fatty acids-like 4 (ELOVL) (150,167), but their roles in AMD
pathogenesis are controversial.
The role of angiogenesis regulators as susceptibility genes for AMD has also been
studied, but the genetic association studies on the role of VEGF polymorphisms in the
exudative AMD have resulted into conflicting results (168-171). However, there is
some evidence on the association between polymorphisms of the gene encoding the
antiangiogenic pigment epithelial growth factor (PEDF) and AMD (172,173).
2.3 Pathophysiological changes in obesity
A long-term imbalance between energy expenditure and intake has harmful systemic
effects (Figure 1), many of which are attributable to adipose tissue dysfunction
(48,174,175). In addition to increased adipocyte size which itself is an independent
marker for metabolic abnormalities (176), other adverse events take place in the adipose
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tissue. The number of preadipocytes and mature adipocytes is in a dynamic equilibrium,
which is regulated by various stimuli, including nutritional status (177) and exposure to
medication and cytokines and other signalling molecules (178,179). In obesity, this
equilibrium is disrupted, as obese individuals have approximately three-fold higher
necrosis rate of adipocytes in comparison to lean persons (180). Impaired adipocyte
differentiation has also been demonstrated in insulin resistant states (181-183) and this
probably accounts, at least in part, for both the increased serum free fatty acids (FFAs)
and  the  altered  pattern  of  adipokine  secretion  observed  in  obesity.  One  of  the  crucial
events is the activation of the Wnt-signaling pathway which, in turn, impairs normal
adipocyte differentiation as well as the secretion of adipokines (182-184).
The connection between inflammation and adipocyte differentiation is highlighted
by the negative correlation between the degree of adipocyte differentiation and
activation of proinflammatory molecules. For example, undifferentiated human
preadipocytes express high levels of many proinflammatory genes, which are then
downregulated as the cells differentiate (48) and the classic proinflammatory factor,
tumour necrosis factor  (TNF-) has been shown to inhibit normal adipogenesis by
inhibiting the Wnt pathway (184). Inflammation, together with the other consequences
of adipocyte hypertrophy causes metabolic stress in the endoplasmic reticulum (ER) and
mitochondria (185,186), which can have detrimental effects on lipid and cholesterol
metabolism (185,187).
Normally, adipocytes have a large capacity to synthesize and store triglycerides
during feeding and to hydrolyse and release triglycerides as FFAs and glycerol during
the fasting state (188,189). During the early stages of excess energy intake, the
adipocytes continue to actively store additional triglycerides and maintain a nearly
normal rate of lipolysis during fasting (190). Circulating FFA levels can become
elevated, but skeletal muscle maintains high insulin sensitivity (191). As the energy
imbalance continues, the enlarged adipocytes develop a diminished capacity to store fat
and their endocrine functions change so that they produce excessive  amounts  of
cytokines that promote inflammation, atherosclerosis and insulin resistance (48,175).
When adipocytes become insulin-resistant, they fail to secrete normal amounts of
insulin-sensitizing adipokines. This sets off a vicious cycle further promoting insulin
resistance and evoking chronic low-grade inflammation which further disposes to other
metabolic diseases such as metabolic syndrome and T2D (48,175,192). These changes
in adipocyte function and lipid metabolism can ultimately result in ectopic fat
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accumulation and lipotoxicity in various tissues when the fatty acid spillover exceeds
the needs of oxidative metabolism and enhances metabolic flux into harmful
nonoxidative metabolism pathways (193). One of the complications of obesity that
seems to be related to these processes is non-alcoholic fatty liver disease (NAFLD), a
spectrum of liver damage including steatosis and fibrosis (194-196). NAFLD is defined
as an excess of fat in the liver in which at least 5% of hepatocytes display lipid droplets
(197).
In addition to these inflammatory and insulin-sensitizing effects, the secreted
compounds are involved in many diverse processes, including the regulation of
neovascularization and the extracellular matrix (198-200). For example, monobutyrin
has been shown to act as an adipose tissue-specific promoter of angiogenesis (201).
Other well-known adipose tissue derived angiogenesis regulators include VEGF,
transforming growth factor  (TGF-) and leptin (198-200,202-204). Angiogenetic
changes have been described, both in obese (202) and hyperglycaemic states (205,206).
Figure 1. A simplied diagram showing the pathophysiological changes in obesity. NAFLD non-alcoholic
fatty liver disease, T2D type 2 diabetes, WAT white adipose tissue
31
2.3.1 Glucose homeostasis in obesity
Insulin resistance that accompanies obesity is related to a deterioration in glucose
disposal in peripheral tissues, including skeletal muscle and adipose tissue, but also in
liver (207,208). Obesity contributes to alterations in glucose metabolism in different
ways, including, but not exclusively due to, enhanced lipolysis, lipotoxicity, elevated
serum FFA concentrations and dysregulation in fat accumulation, mitochondrial
function and cytokine production in peripheral tissues (174,193,209,210).
Increased lipolysis results in elevated levels of circulating FFAs and triglycerides,
thereby contributing to lipid overload and the flow of fatty acids into skeletal muscle
and liver and interfering with the insulin signalling pathways in the skeletal muscle
(174,210-212). The hypothesis that FFAs are the mediators of insulin resistance  is
consistent with the strong association between obesity, insulin resistance and high
circulating FFA levels (213) and the observation that elevated levels of circulating
FFAs can cause peripheral insulin resistance in both animals and humans (214,215).
Moreover, acute lowering of FFAs with an antilipolytic drug (Acipimox; 6-methyl-1-
oxido-pyrazine-2-carboxylic acid) has been shown to enhance the ability of insulin to
promote glucose uptake in peripheral tissues (216). It has been shown that FFAs
compete with glucose as fuel for skeletal muscle and can thereby cause impaired
glucose uptake and failure of insulin to suppress hepatic gluconeogenesis
(214,217,218).
In addition to the distribution of lipids, the proliferation and differentiation
capacity of adipocytes have been suggested to contribute to the altered glucose
metabolism occurring in obesity. Enlarged abdominal adipocytes have been shown to
predict the development of type 2 diabetes independently from insulin resistance and
insulin secretion (176). Impaired fat oxidation has also been suggested to cause ectopic
fat accumulation, since the inhibition of fat oxidation was shown to increase
intracellular lipid content and to decrease insulin action in rats (219). In humans,
decreased postabsorptive fat oxidation was shown to predict weight gain and to be
associated with reduced insulin sensitivity (220,221). This "inadequate fat oxidizing
machinery" as proposed by Heilbronn et al (209) may result from decreased
mitochondrial capacity (222) and lower mitochondrial DNA copy number among obese
individuals (223), although these hypotheses have been challenged by data from mouse
studies (224-226). In addition, changes in sympathetic nervous system activity have
been proposed to affect the fat oxidation capacity (227,228). Interestingly, in the study
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of Perseghin et al (229) with nonobese and obese individuals with similar insulin
sensitivity and intramyocellular lipid content, the obese individuals were shown to have
higher fasting lipid oxidation rates. This indicates that increased fat oxidation might be
an adaptative mechanism that is aimed at maintaining normal intramyocellular lipid
concentrations and insulin sensitivity despite the increase in the amount of body fat.
The role of adipose tissue in glucose homeostasis is further illustrated by the
observation that an insufficient mass of adipose tissue is associated with elevated
circulating triglyceride and fatty acid concentrations and leads to insulin resistance, both
in mice (230-232) and humans (233-235). The observations from humans with
lipodystrophies have demonstrated that inadequate adipose tissue mass leads to ectopic
fat storage in liver, pancreas and skeletal muscle, which then may trigger insulin
resistance and other metabolic alterations (235,236). Lipodystrophies are linked to
insulin resistance also via impaired adipokine secretion (237-239). For example,
individuals with lipodystrophies have low circulating levels of leptin and adiponectin
(238) and the administration of leptin has been shown to improve the glycaemic control
and to decrease serum triglyceride levels in lipodystrophic patients (237).
In contrast to individuals with lipodystrophy, obese persons have a large mass of
adipose tissue, although they have similar metabolic perturbations. Therefore, it has
been suggested that obesity is another ectopic fat accumulation syndrome because the
adipose tissue is not sufficient to store the excess energy (209). This is in line with the
increased content of triglycerides within skeletal muscle in obesity and T2D (215), the
strong association between the increased intramyocellular lipid content and insulin
resistance (209,210,235,240) and the concept that fatty acid overload in pancreas results
in  -cell  dysfunction  and  apoptosis  (193).  The  association  of  hepatic  fat  content  with
insulin resistance (241) and impaired suppression of hepatic glucose production by
insulin (242) also support this hypothesis.
2.3.2 Lipid metabolism in obesity
The connection between obesity and serum lipid and lipoprotein levels has been
established in many large epidemiological studies, including the Framingham Heart
Study (243,244). Changes in body weight have also been shown to result in alterations
in  serum lipoprotein  concentrations  and  thereby  to  affect  the  risk  of  atherogenic  traits
(245). The serum concentrations of total and low-density lipoprotein (LDL) cholesterol
are generally increased and the concentrations of HDL cholesterol, an acceptor of
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cholesterol efflux, are decreased in obese individuals (244,246), and these are believed
to account for at least some of the increased risk of cardiovascular events (245,247).
During constant positive energy balance both the triglyceride pools of adipose tissue
and triglyceride synthesis in the liver are increased. This promotes the overproduction
of very low density lipoprotein (VLDL)-triglycerides in obese people (248,249). The
excess production is stimulated by constant, increased influx of nutrients into the liver
as excess energy is derived from the diet in the postprandial state (190,250), and the
plasma concentration of FFAs is increased in the fasting state (191,192). The increased
input of fatty acids into the liver may be accentuated by central obesity, because visceral
adipose tissue directly releases fatty acids into the portal circulation (45).
 Obese individuals have lower cholesterol absorption rates (251), but their
cholesterol synthesis is increased in comparison to individuals with normal body size
(252).  Weight reduction has been shown to increase the absorption of cholesterol (253).
Restriction of caloric and dietary sterols has been shown to decrease cholesterol
synthesis and improve glycaemic control in obese individuals with T2D, linking glucose
and lipid metabolism (254). The production of VLDL-triglycerides and consequently,
VLDL-apolipoprotein B and LDL-apolipoprotein B are increased in obese individuals
(249,255-258). The elevated concentrations of VLDL- and LDL-particles suppress
LDL-receptor activity and thereby raise the serum LDL levels (248,249,258). Excessive
intake of saturated fatty acids and cholesterol have been suggested to contribute to
overproduction of VLDL, and consequently, to the higher production of LDL (250,259).
However, the high-fat diet-induced elevations of total and LDL cholesterol levels result
mainly from suppressed LDL receptor activity (260,261).
The reduced HDL concentrations in obesity (246) have been suggested to result
from the increased synthesis of LDL which drains away HDL-cholesteryl esters and
HDL-apoA-I thereby limiting the HDL synthesis (248,262). Another hypothesis is that
the excess adipose tissue simply removes HDL from the circulation (246).
Many of these changes are identical to the characteristic disturbances of lipid
metabolism occurring during the acute-phase response to infection as well as
inflammation (263), and the major acute-phase reactants CRP and serum amyloid A
(SAA) have been shown to be involved in the rapid recycling of cholesterol (264).
During the acute-phase response, the cytokine-mediated changes in lipid metabolism are
aimed at decreasing the toxicity of harmful biological and chemical agents by
redistributing nutrients to cells which are important in host defense (264-267). The
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inflammatory cascade induces a decrease in HDL, impaired reverse cholesterol
transport, elevated serum triglycerides, changes in serum apolipoproteins, related
enzymes, antioxidant capacity and adenosine tri-phosphate binding cassette A1
(ABCA1)-transporter dependent cholesterol efflux (263,266-268). Thus, increased
serum triglycerides and decreased HDL, the classic lipid changes associated with the
metabolic syndrome and T2D, could be regarded also as a highly conserved
evolutionary response aimed at tissue repair (264).
2.3.3 Angiogenesis in obesity
Adipogenesis and angiogenesis are temporally and spatially coupled processes during
embryogenesis and their reciprocal crosstalk via paracrine signaling systems continues
throughout adult life (202). Each adipocyte is nourished by a well-organized capillary
network in normal weight individuals (203,204,269). Adipocytes and other cells in the
adipose tissue produce many angiogenic factors including angiopoietins, hepatocyte
growth factor, VEGF and TGF-, but also traditional adipokines such as leptin and
adiponectin have been suggested to be involved in the regulation of angiogenesis
(Figure 2) (203,204,270,271).
The common ground between adipogenesis and angiogenesis is highlighted in
several ways: human adipose tissue–derived stem cells can differentiate into endothelial
cells and improve postnatal neovascularization (270), and adipocytes and their
accompanying endothelial cells seem to share a common progenitor that can
differentiate into adipocytes or endothelial lineages depending on the type of exposure
in different environments (272). Accumulating evidence shows that capillary
endothelial cells communicate with adipocytes via paracrine signaling pathways,
extracellular components, and direct cell-cell interactions (204,273,274).
These two processes also share some common molecular factors such as PPAR-
and VEGF. PPAR-, an essential mediator of preadipocyte differentiation, is involved
in the regulation of adipose tissue angiogenesis and inhibition of adipocyte
differentiation by overexpression of a dominant-negative PPAR- construct (Leu468 and
Glu471Ala) has been shown to impair both adipogenesis and angiogenesis (275). It
has also been shown that rosiglitazone, a PPAR- agonist, stimulates angiogenic
sprouting in adipose tissue fragments (276). The inhibition of the VEGF signalling
system also inhibits angiogenesis and preadipocyte differentiation (275). The role of
adipose tissue-derived VEGF in angiogenesis was recently highlighted by Ledoux et al
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(277), who also demonstrated that both subcutaneous and visceral depots have
equivalent angiogenic potencies.
Figure 2. Angiogenetic factors secreted by adipose tissue (modified from Cao 2007 (202)). Different cell
types of adipose tissue contribute to the production of pro- and antiangiogenic factors. In addition, leptin
indirectly stimulates the secretion of VEGF. IL interleukin, TGF- transforming growth factor-, TNF-
tumour necrosis factor-, VEGF vascular endothelial growth factor
Recently, it was reported that also macrophages may stimulate angiogenesis in
adipose tissue by secreting platelet-derived growth factor and that way they can regulate
the tube formation of endothelial cells (278). The secreted compounds stimulate
neovascularization during fat mass expansion, either acting alone or in co-operation
with other angiogenic factors (202-204,270). Since the secretion of these factors is often
induced by hypoxia, it has been suggested that expansion of adipose tissue is associated
with local hypoxia. In agreement with this hypothesis, the tip region of epididymal
adipose tissue in adult mice is extremely hypoxic and expresses high levels of
angiogenesis-promoting factors (279).
It has been speculated that when the growth rate of adipose tissue becomes
stabilized,  high  expression  levels  of  angiogenesis  inhibitors  are  required  to  restrict
further vessel growth (202). In agreement with this hypothesis, expression of
36
thrombospondin-1 (TSP-1), a well-known angiogenesis inhibitor is downregulated in
preadipocytes and upregulated in differentiated adipocytes (280,281). Administration of
angiostatin, endostatin, and TNP-470 (5-Methoxy-4-(2-methyl-3-(3-methyl-2-butenyl)-
1-oxaspiro(2,5)oct-6-yl(chloroacetyl)carbamate), a compound that arrests the
endothelial cell cycle, results in a dose-dependent and reversible weight reduction and a
loss of adipose tissue in both genetic and diet-induced obesity in mice. Since angiostatin
and endostatin specifically target endothelial cells, these effects are solely due to the
antiangiogenic properties of these molecules (282,283).
The altered vascularization in obesity has been demonstrated in animal models: the
fat pads of obese mice have increased vascularization (284) and fat pads of obese rats
have increased perfusion and decreased vascular resistance (285). Voros et al (284)
showed that the increased blood content of adipose tissue in obese animals was not only
the consequence of functional modulations but also resulted from the growth of the
vascular network. In the same study, the protein expression of angiogenesis-promoting
angiopoietin-1 was lower, and the expression of TSP-1 was higher in the adipose tissue
of ob/ob mice when compared to the corresponding expression levels in the wild-type
mice. Recently, Varma et al (286) confirmed the previous observations on the TSP-1
expression in intra-abdominal adipose tissue in humans (287) and showed that TSP-1 is
a true adipokine, preferentially expressed in the adipocyte fraction and with higher
expression levels in obese, insulin-resistant individuals.
2.3.4 Chronic low-grade inflammation in obesity
Adipocytes and macrophages have the same evolutionary origin: the fat body which is
still present in insects has diverged to liver and adipose tissue during vertebrate
evolution  (288).  The  common  origin  of  these  organs  is  still  visible  in  the  similar
organization of metabolic cells, i.e. adipocytes or hepatocytes, in the close proximity to
inflammatory cells (macrophages or Kupffer cells). This has been proposed to account
for the links between adiposity, inflammation and metabolic disorders (289).
Adipocytes and macrophages share several functional similarities: under appropriate
stimulation, preadipocytes can achieve phagocytotic capacity (290) while macrophages
can also take up and store lipids. The gene expression profiles of these cells also
resemble each other: for example the transcription factor PPAR-, fatty acid binding
protein aP2, interleukin (IL)-6 and matrix metalloproteinases are expressed in both
macrophages and adipocytes (291-294).
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Consistent with these findings, a gain in weight can evoke many inflammation-
related changes in the adipose tissue (Figure 3) (289,295). Furthermore, obesity is
associated with a chronic low-grade inflammation state, characterized by abnormal
cytokine production, increased serum concentrations of acute phase reactants and other
inflammatory mediators and activation of inflammatory signalling pathways (289,295-
297). The obesity-related inflammation seems to be one of the common links between
defects in fatty acid metabolism and insulin resistance (298). The elevated levels of
proinflammatory substances including TNF-, SAA and IL-6 alter the lipid-storing
capabilities and affect insulin sensitivity by increasing lipolysis and decreasing
triglyceride synthesis (174,299-304). This results in elevated circulating FFA
concentrations, higher availability of triglycerides and accumulation of fatty acid
derivatives in the skeletal muscle, liver and -cells, disrupting the normal metabolic and
secretory functions in these tissues (210,211).
Figure 3. Obesity-induced inflammation-related changes in adipose tissue (modified from Schenk et al
2008 (295)). Weight gain results to increased necrosis rate of adipocytes and thereby the characteristic
inflammatory response is evoked. This includes the increased production and release of proinflammatory
cytokines and chemokines and the recruitment of macrophages. The increased secretion of
proinflammatory substances further stimulates the chronic low-grade inflammation.
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The obesity-stimulated inflammatory response has been suggested to be mainly
triggered by adipose tissue, although other metabolic sites, such as liver are also likely
to be involved (293,305). In obesity, the secretion of proinflammatory factors is
upregulated and the secretion of anti-inflammatory factors such as adiponectin is
downregulated (200,297,306). Specifically, increased visceral fat is associated with a
shift in the normal balance of these adipokines resulting in a pro-inflammatory state
(44). Macrophages are the main targets for many of the secreted proinflammatory
substances and accordingly, obesity is associated with an increased accumulation of
macrophages in adipose tissue (307). The macrophages in obese individuals are in a
proinflammatory state, which is reflected in the high levels of secreted TNF- (308).
One of the factors contributing to macrophage infiltration in adipose tissue is the
monocyte chemoattractant protein-1, a chemokine (C-C motif) receptor (CCR)-2 ligand
(309) which is upregulated in obesity (310). Recently also CCR-5 receptor and its
ligand chemokine (C-C motif) ligand (CCL)5, also known as regulated upon activation,
normally T-expressed, and presumably secreted (RANTES), have been shown to be
upregulated in the adipose tissue of obese human and rodents (306).
Inflammatory and metabolic processes are coordinately regulated by many
transcription factors, such as PPARs and liver X receptors (311,312). Ligands of all
three PPARs suppress production of proinflammatory mediators, mainly by inhibiting
nuclear factor B (311,312). Reciprocally, TNF- decreases the expression of
adipocyte-specific genes and transcription factors which are necessary for adipocyte
differentiation, including PPAR- and CCAAT/enhancer-binding protein  (C/EBP-)
(313,314). Liver X receptor is also able to suppress the production of inflammatory
mediators (315). Interestingly, the activation of liver X receptor improves glucose
tolerance by regulating glucose metabolism in liver and adipose tissue (316). This,
together with the anti-inflammatory properties of insulin (317) and the insulin-
sensitizing actions of adiponectin (318) represents a bridge between inflammation and
the characteristics of obesity and impaired glucose metabolism.
2.3.5 Effect of weight change on gene expression in peripheral tissues
It has been shown that weight loss can induce changes in the gene expression in human
adipose tissue (319-325), but also in other tissues such as skeletal muscle (326,327) and
peripheral blood mononuclear cells (328). In humans, the effects of overfeeding in
controlled clinical settings have been studied to a lesser extent, but also a positive
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energy balance has been shown to affect transcription levels (329,330). In addition to
the energy content, the composition of diet, such as the amount (331) and quality of fat
(332,333) and the amount (319,332-334) and glycaemic index of consumed
carbohydrates (335) of isocaloric diets all are factors which can influence the
transcription of genes in different tissues.
Meugnier et al (330) have reported that overfeeding alters the gene expression
profile of skeletal muscle. At the same time, these changes stimulate triacylglycerol
synthesis and the development of adipocytes, inhibit lipolysis and reduce fatty acid
oxidation. Promoter analysis of the regulated genes showed that sterol regulatory
element binding proteins (SREBPs) might be important players in the short-term
adaptation to fat overfeeding in human skeletal muscle. Accordingly, excess energy
intake has been shown to increase the mRNA expression of SREBP-1c in both
overweight and lean individuals (329).
As expected, weight reduction downregulates the mRNA expression of leptin,  IL-6
(319,331) and other proinflammatory factors and upregulates the expression of mRNAs
encoding anti-inflammatory factors (323). Many of the genes involved in fatty acid and
cholesterol metabolism, such as hormone-sensitive lipase (HSL) (331,336), fatty acid
synthase (FASN), fatty acid translocase (CD36), lipoprotein lipase (LPL) (331),
diacylglycerol O-acyltransferase 2 (DGAT2) (333), fatty acid desaturase (FADS1),
stearoyl conezyme A desaturase (SCD) (333,334), 3-hydroxy-3-methyl-glutaryl-CoA
reductase (HMGCR) and LDL-receptor (332) are also downregulated by weight loss,
both in adipose tissue (331,333,334) and mononuclear cells (332).
In a recent study, the genes defined by gene ontology groups of the extracellular
matrix and cell death were differentially regulated in adipose tissue by long-term weight
loss in persons with the features of metabolic syndrome (325). One of the most
extensively downregulated genes was tenomodulin (fold change 0.67). In that study, the
participants underwent a 12-week intensive weight reduction and were expected to
maintain their reduced weight for the following 20 weeks. A change of similar
magnitude in TNMD expression (0.75) was observed by Dahlman et al (334) when they
compared the effects of two different diets during a 10-week weight loss period.
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2.4 Tenomodulin
2.4.1 Structure and function of the tenomodulin gene and protein
Tenomodulin was identified in 2001 by Cros et al (337), who demonstrated that a novel
gene which they named myodulin, was two-fold downregulated in muscle atrophy in
mice. Simultaneously, other groups cloned the same gene and named it
chondromodulin-I-like (338), tenomodulin (339), and tendin (340). The tenomodulin
gene spans approximately 15 kb in chromosomal locus Xq22. TNMD has at least three
splice variants. In addition to the variant containing seven exons (341), a five-exon
splice variant is described in the UCSC Genome Browser (342), March 2006 Assembly
(http://genome.ucsc.edu/) and a three-exon variant in Ensembl´s Vega Transcript Report
((343), v.31 April 2008; http://vega.sanger.ac.uk/). The functions and tissue distribution
of these shorter transcripts have not been characterized.
TNMD belongs to the BRICHOS protein family (344). In a similar manner to the
other members of this family, TNMD is an integral type 2 transmembrane protein with
cytoplasmic N-terminal and extracellular C-terminal, from which the C-terminal part is
cleaved proteolytically (344,345). While two other members of the BRICHOS-family,
chondromodulin (CHM) and familial dementia BRI2 have a furin cleavage site, TNMD
contains an RXXR-cleavage motif (amino acids 233-236) that has been shown to be
functional  (345).  The  TNMD  protein  is  composed  of  short  N-terminal  cytoplasmic
domain (residues 1-30), a transmembrane domain (residues 31-51), BRICHOS-domain,
which has been suggested to function as an intramolecular chaperone for the cleaved
part (344,346) (residues 93-186) and a cysteine-rich C-terminal antiangiogenic domain
(residues 202-317) (337). Similar structural components are found in the CHM (Figure
4) (341).
TNMD does not have any close homologs, but it exhibits overall 33% amino acid
sequence identity with CHM, which is a chondrocyte growth factor (347) and
angiogenesis inhibitor (348). The similarities in the structural organization between
these two proteins are rather apparent (Figure 4).
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Figure 4. The domain architecture of human chondromodulin (CHM) and tenomodulin (TNMD) proteins
(according to Oshima et al 2004 (349)). Different domains are indicated with greyscale. The furin
cleavage site in the amino acid position 211-214 in CHM and RXXR-cleavage site in the position 233-
236 in TNMD are denoted by asterisks (*) and the eight conserved cysteine residues by C.
The  sizes  of  unprocessed  CHM  and  TNMD  precursors  are  almost  identical:  CHM  is
composed of 334 amino acid residues while TNMD consists of 317 amino acid residues
(341). Although the sequence similarity of this domain is quite high (65%), and the
cysteine residues that are needed for the correct folding are identically spaced in both
CHM and TNMD (345,347,348), the molecular weight of secreted part is different. The
secreted part of TNMD is only 16kDa (345), while that of CHM is 25 kDa (347,348).
The exact targets of this domain are unknown.
Functional studies performed in vitro have shown that the secreted parts of both
CHM and TNMD inhibit angiogenesis by preventing endothelial proliferation and tube
formation (349,350). However, TNMD-deficient mice did not exhibit any vascular
abnormalities (345), though this could be due to compensatory mechanisms which
maintain normal vasculature in the absence of tenomodulin. In addition, in vivo studies
performed in mice (345,351) and chicks (352)  have demonstrated the necessity of
TNMD for tenocyte proliferation and tendon maturation.
2.4.2 Expression profile and tissue distribution
TNMD is mainly expressed in hypovascular connective tissues such as tendons,
ligaments and eye. The main results from mouse studies are summarized in Table 4.
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Table 4. The expression of tenomodulin mRNA and protein in mouse tissues. RT-PCR reverse-
transcriptase-polymerase chain reaction
Tissue Expression level Method Author
Skeletal muscle (whole) High Northern blot,
RT-PCR
Cros et al (337)
Yamana et al (338)
Shukunami et al (339)
Brandau et al (340)
Skeletal muscle (epimysium
envelope and  tendon)
High In situ
hybridisation
Shukunami et al (339)
Skeletal muscle (ligament and
tendon)
High In situ
hybridisation
Brandau et al (340)
Whole rib High RT-PCR Yamana et al (338)
Thymus and brain High In situ
hybridisation
Brandau et al (340)
Eye (whole) High Northern blot Yamana et al (338)
Brandau et al (340)
Oshima et al (350)
Eye (cornea, sensory retina,
lens fiber and sclera)
High In situ
hybridisation
Oshima et al (350)
Eye (choroidal tissues, e.g.
retinal pigment epithelium)
Low In situ
hybridisation
Oshima et al (350)
Tenomodulin has not been reported to be expressed in the adipose tissue of mice,
but it has been shown to be expressed in human adipose tissue (325,334). It is not
known which actual cell types in the adipose tissue express tenomodulin, but according
to Gene Atlas database ((353) http://symatlas.gnf.org/SymAtlas/), TNMD expression is
detected in the adipocytes, albeit at a modest level. In addition, our preliminary studies
have shown that TNMD is expressed in adipocytes and blood vessels of adipose tissue
(unpublished observation). Other human tissues that exhibit relatively high mRNA
expression of TNMD are cardiac myocytes, tongue and certain regions of brain, such as
temporal lobe and globus pallidus (353).
2.4.3 Regulators of tenomodulin expression
The regulators of TNMD expression  are  not  very  well  known.   Scleraxis  (SCX),  a
transcription factor and a tendon-specific marker (354), has been shown to upregulate
TNMD expression in chick embryo and tenocyte cultures (352). Recently, Mendias et al
(351) reported that myostatin (MSTN) upregulates TNMD expression in tendon
fibroblasts. Myostatin, also known as growth and differentiation factor 8 is a member of
TGF- superfamily, a large group of secreted growth and differentiation factors that are
essential for regulation of tissue development and homeostasis. The members of this
family are involved in myogenesis, angiogenesis and adipogenesis (202,355-357).
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Myostatin deficiency also influences the mechanical properties of tendons, as MSTN-
deficient mice have been shown to have stiff and brittle tendons with significantly lower
TNMD expression than their wild-type counterparts (351).
The MSTN gene has been widely studied, since the alterations in its expression
affect the body composition. MSTN-deficiency causes muscle hypertrophy (356-
361,361,362) and overexpression leads to decreased adipogenesis (363,364). The
importance of myostatin in adipose tissue development has been proven both in vitro
and in vivo. Rebbapragada et al (365) first demonstrated that MSTN blocks
adipogenesis in both mesenchymal precursor cells and preadipocytes. Subsequently,
Feldman et al (364) showed that myostatin modulates adipogenesis so that the
generated adipocytes had favourable metabolic characteristics including reduced lipid
accumulation, diminished incorporation of exogenous fatty acid into cellular lipids and
high insulin sensitivity. The cells resembled immature adipocytes, since they were
smaller than normal adipocytes and displayed low expression levels of LPL, PPAR-,
leptin, adiponectin, TNF- and resistin. In the study of Zimmers et al (366), the
pharmacological administration of myostatin in adult mice reduced fat mass by up to
50% without affecting muscle mass, but these results have not been successfully
duplicated (367). MSTN has not been studied in the context of human obesity, but it has
been  claimed  that  weight  loss  significantly  downregulates  the  expression  of MSTN in
the skeletal muscle of morbidly obese persons (368).
2.4.4 Tenomodulin knock-out mouse
Docheva et al. (345) have reported that the ablation of TNMD expression by gene-
targeting did not affect the viability or life span of mice. The body size, weight, basic
histology of the main organs (muscle, thymus, heart, liver, spleen, and lung) or skeletal
development were not affected by TNMD deficiency.
The TNMD-knock-out (KO) mice had a reduced tenocyte density due to impaired
proliferation and an altered structure of collagen fibrils. However, despite the lower cell
numbers, the tendons of KO mice were of the same size as those measured in the wild-
type (WT) mice, suggesting that either the remaining tenocytes were able to compensate
for the loss of cells or that the turnover of extracellular matrix was delayed in the
TNMD-deficient tendons. The tendons of TNMD-null mice also exhibited greater
variation in collagen fibril diameters and an increase in the maximal fibril diameters in
comparison to WT mice. Interestingly, knock-out of TSP-2 gene, a close homolog of the
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adipokine TSP-1 (369), results in similar phenotype in the tendons of these knock-out
mice (370).
At odds with the previously reported antiangiogenic activity (349), a loss of TNMD
expression did not affect tendon vessel density and mice lacking both TNMD and CHM
had normal retinal vascularization and neovascularization after oxygen-induced
retinopathy (345). Similarly, the deletion of the TSP-1 gene  in  mice  did  not  result  in
severe vasculature-related abnormalities (371).
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3 AIMS OF THE STUDY
Two  independent  studies  have  shown  that  weight  loss  decreases  the  expression  of
TNMD in the adipose tissue (325,334). TNMD mediates antiangiogenic effects
(349,350), and recently another angiogenesis inhibitor, TSP-1, was confirmed to be an
adipokine (286). Therefore the research hypothesis was that TNMD might  be  a
susceptibility gene for obesity and related conditions.
The  purpose  of  the  study  was  to  investigate  the  association  of  a  common  sequence
variation in the TNMD gene with obesity and related phenotypes. These association
studies were performed in three different study populations, both in longitudinal and
cross-sectional settings. The specific research questions were whether the common
single nucleotide polymorphisms (SNPs) in the TNMD gene would be associated with:
1. Obesity and anthropometric measurements (Studies I and III)
2.  Glucose  metabolism  and  incidence  or  prevalence  of  type  2  diabetes  (Studies I and
III)
3. Chronic low-grade inflammation status indicated by serum levels of systemic
immune mediators (Study II)
4. Serum levels of lipids and lipoproteins (Study III)
5. Prevalence of age-related macular degeneration (Study IV)
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4 SUBJECTS AND METHODS
4.1 Study populations
4.1.1 The Finnish Diabetes Prevention Study (Studies I-III)
The Finnish Diabetes Prevention Study (DPS) is a randomized, controlled lifestyle
intervention study conducted in the cities of Helsinki, Kuopio, Tampere Turku and Oulu
in Finland (82). The main aim of DPS was to investigate whether the onset of T2D
could be prevented or delayed among high-risk individuals by lifestyle modification.
The main inclusion criteria were BMI over 25 kg/m2, age 40 to 64 years and impaired
glucose tolerance tolerance (2h-PG 7.8–11.0 mmol/l and FPG<7.8 mmol/l) on the basis
of the mean value of two consecutive OGTTs. It should be noted that the glucose
tolerance status was diagnosed on the basis of WHO 1985 criteria (60) and according to
the current criteria (62), some of the participants would have been diagnosed with T2D
in the beginning of the study
Altogether 522 individuals were randomized into two groups according to the
centre, gender, and mean 2h-PG in OGTT. The intervention group (n=265) received
intensive individualized diet and exercise counselling and were given detailed advice on
how to achieve the objectives of the intervention, while the control group (n=257)
received general written and oral information about diet and exercise at baseline and
annual visits (82). Medical history questionnaires, anthropometric and laboratory
measurements  were  obtained  at  baseline  and  at  the  annual  visits.  DNA  was  available
from 507 individuals (166 men and 341 women).
 The study protocol was approved by the Ethics Committee of the National Public
Health Institute in Helsinki, Finland and the participants received both oral and written
information of the study and provided written informed consent.
4.1.2 Metabolic Syndrome in Men (Study III)
The Metabolic Syndrome in Men- study  (METSIM)  is  a  random  population-based
sample of 5298 Finnish 50-70 years old men living in the city of Kuopio in Eastern
Finland (113). The primary aim of this ongoing study is to investigate the genetic risk
factors of T2D and cardiovascular diseases. According to WHO´s 1999 criteria (62),
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3020 individuals were normoglycaemic, 984 had impaired fasting glucose, 436 had
impaired glucose tolerance and 811 had known or newly diagnosed T2D.
The Ethics Committee of the District Hospital Region of Northern Savo and Kuopio
University Hospital approved the study plan. The participants received both oral and
written information of the study and gave their written informed consent.
4.1.3 Study population for age-related macular degeneration (Study
IV)
Altogether 475 persons (162 men, 313 women) from the regions of Kuopio and
Helsinki were included in this study. Eighty-nine men and 175 women had exudative
AMD and 18 men and 25 women had atrophic AMD. The control group consisted of 55
men and 113 women. All participants were over 65 years old. Diabetes mellitus, based
on medical history and patient records was considered as an exclusion criterion. The
study was approved by the Ethics Committees of the Kuopio University Hospital and
Helsinki University Eye and Ear Hospital. All participants signed an informed consent.
The controls were patients with other ophthalmologic conditions (e.g. cataract) who had
no signs of AMD in biomicroscopy examination. Age-related macular degeneration was
diagnosed on the basis of choroidal neovascularization in fundus photographs and
fluorescein angiography in the Department of Ophthalmology at Kuopio University
Hospital or Helsinki University Hospital.
4.2 Methods
4.2.1 Anthropometric measurements (Studies I-III)
Weight and height were measured in light clothing and BMI was calculated as the
weight in kilograms divided by the square of the height in meters in both DPS and
METSIM studies. In the DPS, the waist circumference was measured midway between
the lowest rib and iliac crest and hip circumference over the great trochanters in the
standing position. Sagittal and horizontal diameters were measured with the person in
supine position on a hard surface as the distance from the surface to the highest point of
the abdomen (sagittal diameter) and the maximum width of the abdomen (horizontal
diameter) at the level of the iliac crest using especially built equipment. The exact
description for methdology in DPS is described in (83).
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4.2.2 Biochemical and diagnostics measurements (Studies I-IV)
In  both  METSIM  and  DPS,  the  glucose  tolerance  was  determined  by  2h  OGTT  with
75 g glucose dose after an overnight fast. Samples for plasma glucose and insulin
concentrations were drawn at 0, 30 and 120 min.
DPS. The plasma glucose concentrations were determined locally according to standard
guidelines while all other biochemical determinations were performed in the central
laboratory of the Department of Biochemistry, National Public Health Institute,
Helsinki. Serum insulin was determined with radioimmunoassay (Pharmacia, Uppsala,
Sweden). Serum total cholesterol, HDL-cholesterol and triglycerides were determined
with an enzymatic assay method (CHOD-PAP, Boehringer Mannheim, Germany,
Monotest). LDL-cholesterol was calculated with the Friedewald formula (372) and
applied only when triglyceride levels were <4.5mmol/l (83).
The serum concentrations of CRP and SAA were assessed by a high-sensitivity
latex-enhanced nephelometric assay and immunonephelometry, respectively with BN II
analyzer (Dade Behring, Marburg, Germany). Enzyme-linked immunosorbent assay
(ELISA) was used for determining the serum concentrations of IL-6 (Sanguin,
Amsterdam, Netherlands), soluble intercellular adhesion molecule-1 (sICAM-1;
Diaclone, Besancon, France), CCL3, CCL5 and macrophage migration inhibitory factor
(MIF; R&D Systems, Wiesbaden Germany for all three).
METSIM. The biochemical  analyses  were  performed at  the  Clinical  Research  Unit  in
the University of Kuopio. Serum insulin was determined with an immunoluminometric
method  (Avidia  Centaur  IRI)  on  Advia  Centaur  Immunoassay  System  (both  from
Siemens  Medical  Solution  Diagnostics,  Tarrytown,  NY,  USA).  The  plasma  glucose
concentration was determined by the hexokinase method (Thermo Fisher Scientific,
Vantaa, Finland). Serum total cholesterol and triglycerides were analyzed with an
enzymatic method and serum HDL and LDL were determined with direct enzymatic
assays (KoneLab Systems Reagents). KoneLab 20XTi Clinical Chemistry Analyzer was
used for both glucose and lipoprotein analyses.
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4.2.3 Genetic association studies
4.2.3.1 The selection and genotyping of single nucleotide polymorphisms
Studies I-II. The HapMap- (373) and the National Center for Biotechnology
Information databases were used for selection of TNMD SNPs for genotype analysis.
Specifically, two of two tag-SNPs of haploblock 1 (rs5966709 and rs4828037) and three
from five tag-SNPs of haploblock 2 (rs2073162, rs2076163, and rs4828038) were
selected from the HapMap database. The CEPH (Utah residents with ancestry from
northern  and  western  Europe  (CEU)  was  used  as  a  reference  population.  In  addition,
two SNPs were selected from the National Center for Biotechnology Information
database to cover the 5' and 3' ends of the gene (rs11798018 and rs1155974). The
selected markers cover 63% of the common sequence variation with r2>0.8 in the coding
region of TNMD.
Study III. Markers rs2073162, rs2073163 and rs1155974 that were associated with T2D
risk in the DPS (Study I) were genotyped from 2045 participants of the METSIM study,
but as the three markers were in complete linkage disequilibrium (LD), genotyping was
continued only for rs2073162 for the remaining 3253 individuals.
Study IV. Six markers covering 75% of the common sequence variation with r2>0.8 in
the  coding  region  of TNMD (15kb) and 10 kb up-and downstream from the coding
region (35kb) were selected with the Tagger algorithm (374). The markers rs2073163
and rs1155974 were forced in the selection procedure.
Genotyping for all studies was carried out using TaqMan Allelic Discrimination Assays
according to the manufacturer's instructions (Applied Biosystems, Foster City, CA,
USA). The genotyping reactions were amplified using GeneAmp PCR system 2700 and
allelic discrimination according to the fluorescent labels was performed with ABI Prism
7000 sequence detector (both from Applied Biosystems). The error rate for genotyping
was estimated by repeating a random sample of 3.5% of the METSIM study population
and 6.3% of the DPS- and AMD-study populations.
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4.2.3.2 Statistical analyses
Haploview software (375) was used for LD and Hardy-Weinberg equilibrium (HWE)
calculations. Statistical analyses were performed with SPSS14.0 for Windows (SPSS,
Chicago, IL, USA). The data are presented as median (interquartile range) (tables) or
means±standard error of the mean (SEM; figures) and p<0.05 was considered
statistically significant. Due to the X-chromosomal location of the TNMD gene, men
and women were analyzed separately. Data from women was analyzed with the additive
model in Studies I-IV,  and  with  dominant  (major  allele  homozygotes  vs.  other
genotypes) and recessive (minor allele homozygotes vs. other genotypes) models in
Studies II-IV.
The distribution of genotypes among genders and study groups was assessed with
Pearson´s 2-test. Normal distribution was tested with Lilliefors-corrected
Kolmogorov–Smirnov test (Studies I-III) and by plotting the residuals of each statistical
model  (Studies II-III). Appropriate transformations were performed to achieve normal
distribution when necessary. If the distribution of continuous variables could not be
normalized,  Kruskal-Wallis  or  Mann-Whitney´s  U tests  were  used.  The  association  of
TNMD SNPs with continuous variables in Studies I-III was analyzed with a general
linear models using univariate analysis of variance for baseline data and repeated
measurements for follow-up data from baseline and three annual visits. Adjustments for
age, BMI and intervention group were done when necessary, i.e. their contribution to
the model was p<0.1. Bonferroni correction was used in pairwise comparisons between
the three genotypes in women. In addition, the effects of genotype and intervention on
the changes in weight and waist circumference at year 1 (calculated as
measurementbaseline-measurementyear1) were assessed in Study I.
In Study II, three different models with either BMI, waist circumference or 2h-PG as
covariates were constructed on the basis of correlations between systemic immune
mediators and potential adjustment factors in this population (376). Both the main
effects and covariate*genotype-interactions were studied. Due to the observed
interactions,  the  data  was  stratified  according  to  median  2-hour  plasma  glucose
concentration (8.72mmol/l) and genderwise median BMI (29.43 for men, 31.21 for
women) and waist circumference (98.5 for men, 103.25 for women) to study whether
the genotype effect is modified by body size or the status of glucose metabolism. The
overlapping of median categories was analysed by Pearson´s 2-test.
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In Study III, the results were adjusted for age, BMI, use of statin and/or use of
reimbursed cholesterol-lowering medication. Due to observed genotype*BMI-
interactions, additional stratified analyses were performed according to the quartiles of
BMI in METSIM and according to the medians of BMI in DPS due to smaller number
of participants in the DPS. In the METSIM study, the ranges for the quartiles were
16.18-24.58 kg/m2, 24.59-26.72 kg/m2, 26.73-29.40 kg/m2 and 29.41-52.11 kg/m2. In
the DPS, the range for the lower median was 23.50-29.40 kg/m2 and 29.45-44.80 kg/m2
for the upper median.
The  association  of  SNPs with  conversion  of  IGT  to  T2D  was  analyzed  with  Cox
regression using appropriate covariates (Study I). The association of TNMD SNPs with
the prevalence of T2D in the METSIM study population Study III was  analyzed  with
logistic regression (adjusted for age and and BMI). The  associations  of TNMD SNPs
with the prevalence of total AMD and exudative and atrophic subforms were tested with
unadjusted logistic regression (Study IV).
THESIAS 3 (Study I) and THESIAS 3.1 (Studies II and IV) (377) were used for
haplotype analysis of LD-based haplotypes. In studies II and IV, the correction for
multiple hypothesis testing was performed with the false discovery rate (FDR) using Q-
value 1.0 software (378). 0 was estimated with a bootstrap method using 	 range from 0
to 0.9 by 0.05.
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5 RESULTS
5.1 Genotype frequencies and success and error rates
The genotype frequencies in DPS and AMD study populations are shown in Table 5. In
the METSIM population, the frequencies were 65.8% for rs2073162-G and 34.2% for
rs2073162-A. In DPS, all markers except rs4828038 (p=0.01) were in HWE, when the
cut-off of p
0.01 was applied. In the AMD study population, the markers rs7890586
and rs2073163 were not in HWE (p=0.002 and 0.009, correspondingly).
In DPS, the markers belonged to two haploblocks on the basis of their LD pattern
(Figure 5a), the first consisting of markers rs11798018, rs5966709 and rs4828037 and
the second of rs2073162, rs2073163, rs4828038 and rs1155974. In the AMD data set,
two markers, rs11798018 and rs5966709, formed the first LD-based haploblock (Figure
5b) and rs2073163 and rs1155974 made up the second. The frequencies of major
haplotypes of these two blocks in both study populations are represented in Table 6.
In the DPS and METSIM studies, the genotyping success rate was 100% for all
markers. In the AMD study population, the genotyping success rate was 98.5% for
rs7890586, 99.6% for rs1204384, and 100% for markers rs11798018, rs5966709,
rs2073163 and rs1155974. The genotyping error rate was 0% in all study populations.
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Table 6. Frequencies of the major (frequency >0.05) LD-based haplotypes in men and women of the
DPS- and AMD- study populations.
DPS AMD
Markers Men
(n=166)
Women
(n=341)
Markers Men
(n=161)
Women
(n=312)
Haploblock 1 Haploblock 1
rs
11
79
80
18
rs
59
66
70
9
rs
48
28
03
7
rs
11
79
80
18
rs
59
66
70
9
A G T 0.33 0.37 A G 0.39 0.44
C  T  C 0.33 0.35  C  T 0.38 0.33
C G T 0.32 0.25 C G 0.23 0.23
Haploblock 2 Haploblock 2
rs
20
73
16
2
rs
20
73
16
3
rs
48
28
03
8
rs
11
55
97
4
rs
20
73
16
3
rs
11
55
97
4
G T T C 0.43 0.51 T C 0.64 0.61
A C C T  0.22 0.33  C  T 0.30 0.33
G T C C 0.16 0.05
A T T C  0.11 0.07
G C C T 0.06 <0.05
5.2 TNMD, obesity and anthropometric measurements
(Study I)
The observed associations between the TNMD and anthropometric measurements in the
DPS are summarized in Table 7. In the follow-up data analysis, the intervention and
control groups of the DPS were analyzed together, because the allele distribution of
each marker was similar in both groups, and the genotype-randomization group
interaction was statistically non-significant in all analyses.
The SNP rs11798018 was associated with BMI and weight (p=0.038 and p=0.029,
respectively) during the 3-year follow-up in men, but no significant associations were
observed at baseline. The persons with the A-allele had lower BMI than individuals
with the C-allele (Table 7).
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Among the women of the DPS, rs2073162 was associated with horizontal diameter
at baseline. The individuals with the rs2073162-AA genotype had the smallest values.
Furthermore, rs4828037 was associated with the sagittal diameter such that the
individuals with rs4828037-TT genotype had the highest values (Table 7).
Table 7. The observed associations of the TNMD SNPs with anthropometric measurements in the DPS.
Numeric data are given as median (interquartile range).
*adjusted for age
**p for additive model adjusted for age and baseline BMI
During the 3-year follow-up, two markers, rs5966709 and rs4828037, were
associated with central obesity in women. In both cases, participants homozygous for
the minor alleles (5966709-TT and 4828037-CC) had lower values than the individuals
with other genotypes (Figure 6). The associations, apart from that of rs5966709 with
horizontal diameter, were considerably stronger when analyzed with the recessive
model (p=0.007 for waist circumference, p=0.009 for waist to hip-ratio and p=0.003 for
sagittal diameter with rs5966709 and p=0.007 for sagittal diameter with rs4828037).
Gender Marker Genotype Parameter Median(IQ range)
p for
baseline
p for
follow-up
Men rs11798018 CCAA BMI (kg/m
2) 29.70 (4.56)29.01 (4.70) 0.810* 0.038*
rs11798018 CCAA Weight (kg)
90.30 (16.40)
86.60 (15.80) 0.064* 0.029*
Women rs2073162
GG
GA
AA
Horizontal
diameter (cm)
39.40 (4.25)
39.20 (5.00)
38.70 (6.70)
0.038** 0.266**
rs5966709
GG
GT
TT
Waist to hip-
ratio
0.89 (0.08)
0.89 (0.09)
0.87 (0.07)
0.316** 0.028**
rs5966709
GG
GT
TT
Sagittal
diameter (cm)
24.40 (4.68)
24.30 (4.30)
23.00 (3.58)
0.080** 0.014**
rs5966709
GG
GT
TT
Horizontal
diameter (cm)
39.20 (5.48)
39.50 (4.40)
37.95 (5.53)
0.055** 0.043**
rs5966709
GG
GT
TT
Waist
circumference
(cm)
99.00 (16.35)
99.50 (14.50)
94.35 (19.00)
0.068** 0.036**
rs4828037
TT
TC
CC
Sagittal
diameter (cm)
24.40 (4.80)
24.30 (4.40)
23.20 (4.10)
0.015** 0.026**
rs4828037
TT
TC
CC
Waist to hip-
ratio
0.89 (0.08)
0.89 (0.09)
0.87 (0.07)
0.479** 0.056**
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Figure 6. The mean±SEM values of waist circumference (a), WHR (b), horizontal diameter (c), and
sagittal diameter (d) in women according to the genotypes of rs5966709 during the 3-year follow-up
according to recessive model.
To study haplotype effects of haploblock 1 (Figure 5a) on body size measurements
at baseline in women, three-marker haplotypes (markers rs11798018, rs5966709, and
rs4828037) were constructed. Three major haplotypes with frequencies of >0.05 were
observed (Table 6). The results were consistent with the baseline analysis of individual
markers, since in comparison to the carriers of the reference haplotype AGT, the
individuals with the CTC haplotype had a lower sagittal diameter (p=0.044). The former
haplotype includes the rs4828037-C-allele, which was per se associated with a smaller
sagittal diameter.
The genotypes of rs2073162 were not associated with BMI (Study III),  weight  or
indicators of central obesity (p>0.1) in the men of METSIM study population.
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5.3 TNMD, glucose metabolism and type 2 diabetes (Studies
I and III)
In DPS, no genotype differences in insulin and glucose levels were observed at baseline,
except for rs2073162 in women. Specifically, the rs2073162-GG genotype was
associated with lower fasting plasma glucose levels than the other genotypes (p=0.021).
The   median  (interquartile  range)  FPG was  5.89  (0.88)  mmol/l  for  the  carriers  of  GG
genotype, 6.21 (1.03) mmol/l for GA  and 6.16 (0.87)mmol/ for the AA genotype. In
women, the same marker was associated with 2h-PG concentrations during the 3-year
follow-up,  but  contradictory  to  the  baseline  results,  the  lowest  levels  were  observed
with the AA-genotype.
Among the men of DPS, the markers rs2073163 and rs1155974 were associated
with 2h-PG during the 3-year follow-up. The marker rs2073163 was also associated
with conversion of IGT to T2D in men in DPS and a borderline association was
observed with rs1155974. The individuals with the minor alleles (rs2073163-C or
rs1155974-T), which were associated with higher 2-hour plasma glucose concentration,
were approximately two times more likely to develop T2D during the 5-year follow-up
than the major allele carriers. Asimilar association was also observed with rs2073162,
which was not associated with 2h-PG. In women, none of the SNPs contributed to the
risk of T2D. The observed associations with 2H-PG and T2D risk are summarized in
Table 8. The marker rs2073162 was not associated with plasma glucose or serum
insulin concentrations during OGTT in the METSIM study and the prevalence of T2D
was also similar between the genotypes (15.2 vs 15.1%).
Table 8. The observed associations of the TNMD SNPs with 2H-PG during the 3-year follow-up and T2D
risk in the DPS. HR hazard ratio (reported only for statistically significant associations), CI confidence
interval
Marker Gender 2H-PG  Risk genotype T2D riskp* HR (95%CI) p**
rs2073162 Men 0.249 A 2.193 (1.105- 4.354) 0.025
rs2073162 Women 0.013 GG 0.755 (0.473-1.204) 0.238
rs2073163 Men 0.038 C 2.191 (1.092-4.394) 0.027
Women 0.056 TC/CC 1.012 (0.546-1.875) 0.971
rs1155974 Men 0.011 T 1.998 (0.989-4.036) 0.054
Women 0.065 CT/TT 1.082 (0.678-1.728) 0.741
*adjusted for age and baseline BMI
**adjusted for baseline BMI, waist-to hip-ratio, fasting plasma glucose and intervention
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To estimate the haplotype effect of these SNPs in DPS, three-marker haplotypes of
SNPs rs2073162, rs2073163, and rs1155974 were constructed and four major
haplotypes (frequencies >0.05) were observed (Table 6). The most common haplotype
(frequency=0.595) contained the rs2073162-G-, rs2073163-T- and rs1155974-C-alleles,
which were also individually associated with a lower risk of T2D. Interestingly, the
complement haplotype ACT, containing all individual risk alleles, was associated with a
2.3-fold risk for developing T2D (p=0.041; 95% CI, 1.034 to 5.175). Although this
analysis did not uncover a haplotype combination that would explain the results
substantially more than individual markers, the results support those obtained from
single-marker analysis.
5.4 TNMD and low-grade inflammation indicated by the
serum levels of systemic immune mediators (Study II)
The association of the common sequence variation in the TNMD gene with acute phase
reactants (SAA and CRP), proinflammatory cytokines (MIF and IL-6), ligands of CCR-
5, which induce the production of proinflammatory cytokines (CCL3 and CCL5) and
sICAM were addressed. In addition, the effect modification by the status of glucose
tolerance, central obesity and general body size (indicated by 2h-PG, waist
circumference and BMI, respectively) was assessed. As BMI and waist circumference
had almost identical effects, and the low-grade inflammation is more related to the
central  obesity  than  body  size  in  general,  only  the  results  in  the  medians  of  waist
circumference and 2h-PG are reported.
The three markers, rs2073162, rs2073163 and rs1155974, which were associated
with the risk of T2D in men in Study I were associated with serum concentrations of
CRP and SAA so that the individuals harbouring the genotypes (rs2073162-A,
rs2073163-C and rs1155974-T) related to higher T2D incidence had higher serum levels
of the three inflammatory markers (Table 9). The markers rs2073163 and rs1155974
were  also  associated  with  the  serum  levels  of  sICAM  so  that  the  men  with  the
rs2073163-C or rs1155974-T genotypes had higher concentrations than the individuals
with the other genotypes. In addition, two markers, rs5966709 and rs4828037, were
associated with serum levels of CCL5 in men so that the rs5966709-G and rs4828037-T
genotypes had higher serum concentrations (Table 9). In women, the same genotypes
were associated with elevated serum concentrations of CCL3 and the rs5966709-GG,
but not rs4828037-TT genotype was associated with higher CCL5 concentrations. Both
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of these markers were associated with central obesity in women (Study I). Furthermore,
all four markers from the second haploblock (Table 6) were associated with serum
concentrations of MIF and the genotype of rs11798018 was associated with serum
concentrations of IL-6 in women (Table 10).
The genotype effects were modified by the status of glucose metabolism so that the
effect was generally clearer in the individuals who had 2h-PG>median (Tables 9-10). In
addition, central obesity, as reflected in the waist circumference, modified the effect in a
similar manner, i.e., the genotype effect was more pronounced in the upper medians.
This was observed particularly in men. CCL5 was the only exception to this, as the
genotype effects were observed in the lower medians of the obesity parameters. In
general, central obesity modified the association of TNMD with acute-phase reactants,
while the association with CCR-5 ligands were more dependent on the status of glucose
metabolism (Tables 9-10).
As this was an explorative analysis, the multiple comparisons were necessary, and
some of the findings might be false positives. We applied FDR to control for the
multiple hypothesis testing and the FDR for association of rs2073163 and rs1155974
with acute phase proteins and sICAM and those of rs5966709 and rs4828037 with
CCL5  in  men  was  less  than  5%.  The  FDR  was  below  5%  also  for  the  association  of
rs5966709 with CCL3 and CCL5 and those of rs2073163 and rs1155974 with CCL5
and MIF in women.
The single-marker associations were mostly haploblock-specific. The markers from
the second haploblock (rs2073162, rs2073163, rs4828038 and rs1155974) were
associated with serum concentrations of acute-phase reactants in men and with serum
concentrations of MIF in women, while the markers from the first haploblock
(rs5966709 and rs4828037) were associated with CCL3-concentrations in women and
CCL5-concentrations in men. Markers from both haploblocks were associated with
CCL5-concentrations in women. However, the LD-based haplotype analysis did not
reveal a haplotype that explained the association substantially more than any individual
SNP, although the results of the analyses were in line with the single marker analyses
(data not shown).
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5.5 TNMD and serum lipids and lipoproteins (Study III)
The genotype of rs2073162 was not associated with the serum lipid or lipoprotein
concentrations in the unstratified METSIM population, but genotype*BMI interactions
were observed. In subsequent analyses when the data were subdivided according to the
quartiles of BMI, no associations were evident in the three lowest quartiles, but in the
highest quartile, the carriers of the rs2073162-A-allele had higher concentrations of
serum total, LDL and HDL cholesterol than carriers of the rs2073162-G-allele (Figure
7a-c). These differences remained statistically significant after additional adjustment for
cholesterol-lowering medication (p=0.016 for total cholesterol, p=0.033 for LDL and
p=0.038 for HDL). The median (interquartile range) for serum total, LDL and HDL
cholesterol were 5.17 (1.45), 3.23 (1.28) and 1.24 (0.39) mmol/l for the G allele carriers
and 5.25 (1.47), 3.37 (1.29) and 1.27 (0.40) mmol/l for the A allele carriers. No
differences were observed in the triglyceride levels.
In  DPS,  genotype  differences  were  not  observed  in  either  gender  when  all
individuals were included in the analysis, but again genotype*BMI interactions were
observed. In the data stratified by the median of BMI, the genotype was not associated
with the serum lipoproteins or lipids in either median in women or in the lower median
in men. In the upper median of BMI in men, the genotype of rs2073162 was associated
with serum levels of total and LDL cholesterol (Figure 7d-f). The median (interquartile
range) for serum total and LDL cholesterol were 5.26 (1.16) and 3.30 (1.13)  mmol/l for
the G allele carriers and 5.49 (0.97) and 3.60 (1.06 mmol/l for the A allele carriers. No
associations with serum HDL cholesterol or triglyceride levels were observed. The
lower cut-off was very similar in both studies (29.41kg/m2 for the 4th quartile in
METSIM, 29.45 kg/m2 for the upper median in DPS).
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Figure 7. The serum concentrations of total, LDL and HDL cholesterol in the quartiles of BMI (ranges
13.18-24.58 kg/m2 for 1st, 24.59-26.72 kg/m2 for 2nd, 26.73-29.40 kg/m2 for 3rd and 29.41-52.11 kg/m2
for the 4th quartile) in the METSIM study population (a-c) and in the medians of BMI (ranges 23.50-
29.40 kg/m2 for the 1st and 29.45-44.80 kg/m2 for the 2nd median) in the DPS study population (d-f)
according to the genotypes of rs2073162. p is adjusted for the use of cholesterol-lowering medication.
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5.6 TNMD and age-related macular degeneration (Study IV)
In women, markers rs7890586 and 1155974 were associated with total prevalence
(atrophic or exudative form) of AMD and a trend was observed with rs2073163.
Specifically, these differences were due to an unequal prevalence of exudative AMD in
the genotype groups (Table 11). None of the markers were associated with prevalence
of AMD among men.
Haplotype analyses were performed according to the two LD-based haploblocks
(Table 6), one consisting of rs11798018 and rs5966709 and the other of rs2073163,
rs1155974 and rs1204384. Additional analyses were performed for combinations of
individual markers that were associated with AMD (rs7890586, rs2073163 and
rs1155974). Neither of these approaches revealed a haplotype that would explain the
results substantially more than the individual markers (data not shown).
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6 DISCUSSION
6.1 Methodological issues
These association studies were performed in a carefully phenotyped and selected set of
individuals who participated in a lifestyle intervention and were followed up for
approximately four years (Studies I-III), a large, cross-sectional extensively phenotyped
population-based sample of men (Study III) and finally in a smaller set of individuals
for which only limited background information was available (Study IV). In general, the
requirements for genetic association studies have changed during the last years and
especially in the field of complex diseases, large-scale genotyping of large sample sizes
are becoming a pre-requisite for studies that are considered to be of good quality (379).
6.1.1 Candidate gene approach
Genome-wide scans are potential tools for identifying common susceptibility variants
and they can be considered as a new approach for discovering candidate genes. In
comparison to the hypothesis-free genome-wide scans, the traditional candidate gene
studies are hypothesis-driven with the assumption that genes with functions relevant to
the phenotype of interest would represent putative susceptibility genes (380). In our
group, this approach is applied by studying genes whose expression in adipose tissue is
differentially regulated by weight loss. TNMD was selected as a potential candidate
gene since it was one of the most extensively downregulated genes in adipose tissue
during moderate weight loss in overweight individuals with features of the metabolic
syndrome (325). Recently, we have shown that TNMD is expressed in adipocytes and
blood vessels in adipose tissue (Figure 8, unpublished data) and therefore it might be
relevant for the adipose tissue biology. Investigation of the differences in mRNA
expression in adipose tissue of obese and lean subjects has identified candidate genes
for obesity and related traits (381) and led to discovery of novel adipokines (286,382).
Furthermore, combining gene expression profiles from the tissue of interest together
with genetic linkage information has been proposed as a strategy to identify
susceptibility genes for complex traits (383).
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Figure 8. TNMD expression in human formalin-fixed paraffin-embedded adipose tissue. TNMD was
detected with NovolinkTM polymer detection system (Novocastra Laboratories Ltd, Newcastle, UK) using
1:500 diluted TNMD primary antibody kindly provided by Prof. Reinhardt Fässler (Max-Planck Institute,
Martinsried, Germany). TNMD is expressed in a) adipocytes and b) blood vessels (Unpublished data).
6.1.2 Study populations
The  DPS  (Studies I-III) is nowadays considered as a small sample for genetic
association studies (n=507), although one of the original study aims was to investigate
the impact of genetic factors on T2D risk (384). The stratification of a relatively small
population into different groups by randomization and gender further weakens the
statistical power. We handled this issue by applying the mandatory stratification by
gender and used the randomization group as an adjustment factor, because this was
justifiable based on the lack of interaction between the genotypes and randomization
group and the similar allele frequencies in both groups. In Studies II-III, we stratified
the data into medians instead of other quantiles, which would have resulted in smaller
number of individuals in each strata and would have increased in the number of groups
thereby causing power loss. Despite these weaknesses, DPS is a representative sample
of Finnish middle-aged persons who had a high risk for developing T2D, as BMI>25
and IGT were part of the inclusion criteria. It is notable that the study enables the
investigation of long-term gene*environment-interactions, either with regard to lifestyle
modification in general or to specific components of dietary habits or physical activity.
The follow-up data of various quantitative and categorical traits also provides more
information than a single measurement of certain surrogate variable. The comparability
of  measurements  from  different  centres  is  good,  as  this  was  addressed  already  in  the
study design by standardizing the measurement methodologies between the laboratories.
The METSIM study (Study III) is currently cross-sectional, so the research setting is
very different from that applied in DPS. The participants are middle-aged men from the
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region of Kuopio and while the DPS is representative of a population in high risk for
T2D, the METSIM is a population-based sample thereby representing the general
population with the whole range of BMI and glucose metabolism. The advantage of this
cohort is that it is specifically collected for the purpose of genetic association studies
and the sample size is therefore appropriate.
The AMD study population (Study IV)  is  small,  and  especially  the  number  of
controls would need to be increased. This is highlighted in the analysis of studying X-
chromosomal gene which makes the stratification by gender mandatory and further
decreases the size of groups. Moreover, no further background data apart from age and
gender were available from this study population. The number of individuals with
atrophic AMD is too small for investigating the risk factors specifically accounting for
this  subtype,  but  the  original  aim  of  the  study  was  to  investigate  the  association  with
AMD in general.
Since all of the study participants were Finnish, the observed associations are
unlikely to result from population stratification. The Finnish population originates
mainly from a small group of founders and relatively little immigration has occurred
during the last 80-100 generations (385,386). The founder effects are more recent in the
Northern and Eastern Finland, as these regions can be viewed as being "founded" only
in the 1500s (385). The Finnish population has been referred to as a model population
for human genetic studies, especially in the context of linkage mapping (387), and it has
been claimed to offer substantial advantages for genetic studies (388).
6.1.3 Genotyping accuracy
The test for HWE is generally applied as a diagnostic test for genotyping errors (389).
However, HWE of genotype frequencies is a population-based characteristic assuming
discrete generations, random mating in an infinite-sized population and the absence of
selection, mutation or migration. Therefore, the deviations observed in these studies can
be a result of population properties or random chance rather than genotyping error, as
the inspection of discrimination plots did not reveal any unequivocal genotyping
mistakes. In addition, when a marker is associated with the disease, the corresponding
genotypes may no longer actually be a random sample and therefore it can lead to
deviation from HWE (390). As the associations with multiple continuous phenotypes
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were investigated in Studies I-II, the HWE was calculated from all individuals.
Interestingly, in Study IV two of the three markers that were associated with AMD risk
were not in HWE, which is in line with the theory of Li and Li (390).
The genotyping accuracy was also confirmed by re-genotyping a representative
random subsample from each population. The error rate for each studied marker in all
study populations was 0%, suggesting that factors other than genotyping errors must
account for the deviation from HWE.
6.1.4 Statistical issues
Investigating  the  association  of  multiple  markers  with  different  phenotypes  raises  the
issue of multiple hypothesis testing. Traditionally this has been addressed with
Bonferroni-correction or its derivatives, which are considered to be too conservative for
genetic association studies (391).
It should be noted that the results of Study I are not adjusted for testing of multiple
hypotheses, apart from pairwise comparisons in women. In Studies II and  IV, we
applied the false discovery rate (378), indicated as q-values. This approach
simultaneously corrects for the number of phenotypes and markers that are tested.
Statistically significant results (i.e. small p-value)  with  a  high q-value are likely to be
false positive findings. Instead of applying an arbitrary threshold, we chose to report the
exact q-value for each p.
In Study II, the FDR for the main results, i.e. for the associations with acute phase
reactants and sICAM in men and for CCR5 ligands and MIF among women were low,
suggesting that these findings are likely to be "true" and that TNMD might be related to
inflammatory status. Due to the limited power caused by relatively low number of study
participants and the further stratification into different groups, there may be some
undetected associations that would be significant if we had had access to larger study
populations. In addition, some of the observed associations that were no longer
statistically significant after correcting for multiple hypothesis testing (i.e., had
FDR>0.05), might remain statistically significant in a more powerful study.
In Study III, associations of a single marker were studied so the results were not
adjusted for testing of multiple hypotheses testing, although this might be justifiable
because multiple phenotypes were tested. In general, the FDR-computations in Q-value
work better with large number of p-values, although there are no recommendations for
the minimum amount of p-values. Our study contained data for only 4 phenotypes,
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meaning that the number is very low for applying FDR according to Storey et al (378).
Another possibility would have been to utilize a permutation-based method, for
example a modification of the procedure introduced by Kimmel et al (392).
In Study IV, the FDR for the associations of markers rs7890586, rs2073163 and
rs1155974 with AMD was less than 5%, apart from that of rs2073163 with total
prevalence of AMD (q=0.067; Table 11). This suggests that the results are unlikely to
be false positives. However, they should be replicated in a larger study and with
adjustment for possible confounders such as smoking and body size. Due to the low
genotype frequencies, the number of individuals was small in some of the analysis (e.g.
the number of persons with the rs7890586-AA-genotype) meaning that these results are
tentative and should be interpreted cautiously.
6.2 General discussion
6.2.1 Gender differences
Almost  all  of  the  observed  associations  were  gender-specific.  These  differences  can
arise from the genetic locus. X-chromosomal genes often display a significant variation
in expression and function between men and women, partly because of variation in gene
dosages and random inactivation of one of the X-chromosomes in women (393).
Accordingly, women had two times higher tenomodulin expression in adipose tissue
than men (325), evidence of dosage-specific expression levels. TNMD is located
approximately 27000 kb away from the X-inactivation centre (locus Xq13.2-q21-1)
(394), suggesting that the TNMD locus might avoid X-inactivation. The cellular
microenvironment can also differ in men and women because of differences in hormone
levels and gene expression (395).
The X-chromosome is an interesting locus for genetic association studies regarding
serum lipids, since the monosomy of the X-chromosome has been shown to be
specifically related to fat accumulation and serum lipid profile in women. In the study
of Van et al (396) women with Turner´s syndrome (45, X) had higher LDL-cholesterol
and  triglyceride  levels  and  smaller  LDL and HDL particle  sizes  than  women with  46,
XX. These effects were independent of lifestyle, body composition, insulin sensitivity
or hormonal status. As the only characterized difference was the presence of the second
X-chromosome, the authors speculated that the differences in lipid metabolism could be
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due to previously unrecognized disparity in X-chromosome gene dosage (396). Similar
results have been reported by Cooley et al (397). In both studies, the degree of
difference in lipid levels and particle size observed between women with one and two
copies of X-chromosome was similar to the genderwise differences (398,399). One
potential explanation for these observations is that X-chromosome gene or genes are
involved in lipid metabolism or transport. According to this hypothesis, membrane-
bound transcription factor protease, site 2 (MBTPS2, locus Xp22), encoding the site 2
protease that cleaves SREBP, is a key regulator of cholesterol metabolism (400).
Genomic imprinting of X-linked genes could lead to different gene expression in
men and women, since women are normally mosaic for maternally and paternally
inherited active X-chromosomes (XM and  XP, correspondingly), while men are
monosomic for the maternally inherited XM. Interestingly, in women with Turner´s
syndrome, the monosomy for XM is associated with greater visceral fat accumulation
and a more atherogenic lipid profile than monosomy for the paternal chromosome (401).
These differences between 45,XP and 45,XM women parallel the usual metabolic and
adiposity differences seen between women and men (398,399).
6.2.2 TNMD and obesity (Studies I and III)
The sequence variation of TNMD was associated with central obesity in women and
with the general body size, indicated by BMI and weight in men of the DPS (Study I).
We did not detect any association with indicators of body size in the larger cross-
sectional sample of METSIM (Study III), as the sample consisted only of men and only
the markers that associated with T2D risk in men were genotyped. These markers did
not  associate  with  body  size  in  the  DPS  and  since  the  association  with  T2D  was
considered the main result in men, the SNP that associated with body size was not
selected for replication in the DPS. Furthermore, the association with obesity measures
in men was observed in the longitudinal data, which was not available from the
METSIM.
With regard to the genetic association studies in general, without functional assays it
is difficult to know whether the causative variant truly is one of the studied markers or
simply a SNP that is in complete linkage disequilibrium with them, or whether the
associations truly arise from the TNMD locus. However, there are no known obesity or
T2D loci nearby (22,24-27,107,108). Apart from rs2073162, which is a nonsynonymous
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SNP located in the third exon, all of the selected markers were intronic. Therefore, if the
causative variant is indeed one of the selected SNPs, the effect does not result from
altered structural and/or functional properties secondary to the amino acid change.
However, the synonymous SNPs can affect transcription of the protein by modifying
transcription factor binding or the extent of the genemethylation or splicing.
Although tenomodulin is believed to mediate anti-angiogenic effects, its specific
function in adipose tissue is still unknown. In our further studies we have shown that
TNMD expression is induced during adipocyte differentiation (unpublished data). The
genes involved in angiogenesis are an interesting new group of susceptibility genes for
obesity and related traits. It has been shown that targeted induction of apoptosis in the
vasculature of adipose tissue can reverse obesity and normalize metabolism in ob/ob
mice (402), and the administration of angiogenesis inhibitors reverses both genetic and
diet-induced obesity in mice (282,283). It has also been suggested that changes in
adipose tissue blood flow may modulate the -cell dysfunction in T2D in a rat model
(403). However, this data is solely based on animal studies. Still, one possibility is that
tenomodulin could regulate vasculature formation in adipose tissue and thereby also
modulate adiposity, glucose metabolism, and T2D risk. Interestingly, TSP-1 an
angiogenesis inhibitor with a similar knock-out mouse phenotype as TNMD, was
recently shown to be an adipokine that was associated with obesity, adipose tissue
inflammation and insulin resistance (286).
TNMD belongs to the family of BRICHOS-domain containing proteins, most of
which are associated with chronic diseases. These include BRI2, which is linked to
familial British and Danish dementia, chondromodulin-I related to chondrosarcoma,
CA11 related to stomach cancer and surfactant protein C, involved in respiratory
distress syndrome (344). TNMD, like other proteins of this family, is an integral
transmembrane  protein  with  a  type  2  orientation,  from  which  the  extracellular  part  is
cleaved proteolytically. The BRICHOS-domain has been suggested to function as an
intramolecular chaperone for the cleaved part (344-346) and mutations in the BRICHOS
region have been shown to cause endoplasmic reticulum (ER) stress and proteasome
dysfunction (346), providing another interesting functional link to the chronic diseases
caused by misfolded proteins. Chronic excessive nutrient intake has been shown to
cause ER stress in adipose tissue of ob/ob mice and mice fed with a high-fat diet
(404,405). Markers of ER stress are associated with obesity in non-diabetic individuals
(406). It has also been shown that obesity increases ER stress in human subcutaneous
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adipose tissue (407) and that the unfolded protein response, a mechanism aimed to
alleviate ER stress, is activated in subcutaneous adipose tissue of obese humans (408).
Data from cell culture and mouse studies suggest that leptin resistance might be one of
the linking mechanisms (409).
6.2.3 TNMD and glucose regulation (Studies I and III)
The SNPs  of TNMD were  associated  with  2h-PG,  and  consequently  with  risk  of  T2D
during the follow-up of DPS. We did not detect any cross-sectional differences between
the genotypes in men, either in the baseline data of DPS with respect to plasma glucose
or serum insulin levels (Study I), or in METSIM regarding prevalence of T2D, plasma
glucose or serum insulin levels (Study III).
The  METSIM  and  DPS  study  populations  are  essentially  different:  Both  men  and
women were included in the DPS and the sample was collected from five Finnish cities
and their surroundings. The individuals were also relatively homogeneous as all of the
study participants had BMI>25 kg/m2 and IGT. The METSIM study population is a
random sample of men aged from 45 to 70 years and living in the Kuopio area.
Therefore, the range for BMI is considerably larger (16.18-52.11 kg/m2)  and  all  four
glucose tolerance categories were included. Furthermore, in the METSIM study the
prevalence of T2D was determined cross-sectionally, while in the DPS study the
conversion of IGT to T2D was assessed. These differences between the studies might
explain why the association with T2D could not be replicated. In future, when the
longitudinal data from the METSIM becomes available, it will be interesting to see
whether the association observed in the DPS can be replicated, despite the different
baseline characteristics. It might also be that different genes operate in distinct phases of
the development of T2D.
Interestingly, the markers rs2073162 and rs2073163 that were associated with an
elevated  risk  of  T2D  in  the  DPS  are  located  within  the  region  that  encodes  the
BRICHOS-domain, and also rs1155974 is in close vicinity. ER stress has been
suggested to be one of the common links between obesity, T2D and insulin resistance in
adipocytes and liver (186,404,405,410). Treatment of obese and diabetic mice with
chemical chaperones has been shown to result into improved insulin sensitivity in
skeletal muscle, adipose tissue and liver, resolution of fatty liver disease and normalized
hyperglycaemia (411). Another interesting pharmacological link is provided by the
PPAR-agonists, since the treatment of mice with rosiglitazone or macelignan has been
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shown to alleviate ER stress in mouse liver and adipose tissue (412,413), although
pioglitazone treatment did not reduce ER stress in human adipose tissue (407).
6.2.4 TNMD and inflammation (Study II)
The sequence variation of TNMD was consistently associated with serum concentrations
of different systemic immune mediators in individuals with IGT, suggesting that the
chronic low-grade inflammation could be the link between the observed associations of
TNMD with  obesity,  dyslipidaemia,  AMD and T2D. All these states are also strongly
interconnected. In women, the same genotypes that were associated with elevated
concentrations of CCL3 and CCL5 were associated with a larger waistline, as indicated
by all four parameters for central obesity that were measured in Study I. In men, the
genotypes that were associated with the higher risk of T2D, were associated with higher
levels of CRP and SAA. In addition, the same genotype of rs2073162 that was related to
higher acute phase reactant concentrations and T2D risk, was correlated with higher
serum total and LDL cholesterol levels in the obese men and the markers rs2073163 and
rs1155974 that were associated with serum MIF concentrations among women, were
associated with the risk of exudative AMD in women.
Both angiogenesis and ER stress, and, therefore, both of the important functional
motifs of TNMD, namely the angiogenesis inhibiting C-terminal domain and
BRICHOS-domain can be connected to inflammation. Inflammation, together with
other harmful consequences of the expansion of adipose tissue mass, such as hypoxia
and oxidative stress causes dysfunctions in ER (185,186).  ER stress is linked to major
inflammatory and stress-signalling networks via a variety of mechanisms (185,186).
Hypoxia stimulates both angiogenesis and inflammation, but angiogenesis has been
suggested to also sustain inflammation, by providing oxygen and nutrients for the cells
present at the inflammatory sites (414). Angiogenesis and inflammation have been
connected in the pathogenesis of a number of chronic diseases and these two processes
can be initiated by the same molecular events (414). For example, both angiogenesis
and inflammation have actions at the endothelial cell-cell junctions and adhesion
molecules are therefore essential for both processes (415,416). Long-term angiogenetic
imbalance often accompanies inflammation (417) and inflammatory cells are known to
promote (lymph)angiogenesis in tumours (418).
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6.2.5 TNMD and serum lipoproteins (Study III)
The rs2073162-A genotype, which was associated with higher T2D incidence in Study I
and  elevated  serum  concentrations  of  CRP  and  SAA  in Study II, was associated with
elevated concentrations of serum lipoproteins in a BMI-dependent manner in two
independent studies including Finnish men. Specifically, in the METSIM study
differences in total, HDL and LDL cholesterol were observed, whereas in the DPS the
differences were found only in total and LDL cholesterol levels.
The associations were observed in those individuals who belonged to the highest
quantiles of BMI, and the results remained similar when the cut-off of 30kg/m2 was
used. It is difficult to determine whether these differences result from altered cholesterol
absorption or synthesis, since the data on the indicators of cholesterol metabolism was
not available. It has been established that serum total cholesterol is increased in obesity,
partially because of increased cholesterol synthesis (252). In this study, the differences
in serum total cholesterol between the genotypes were almost entirely due to the
difference  in  LDL  cholesterol  levels,  but  as  with  the  total  cholesterol  levels,  one  can
only speculate if they are caused by increased LDL synthesis or by decreased
catabolism. Since both SAA and CRP have been shown to be involved in cholesterol
recycling (264), it is possible that the observed association could be attributable to the
association with low-grade inflammation.
6.2.6 TNMD and age-related macular degeneration (Study IV)
The sequence variation of the TNMD gene was associated with the prevalence of AMD
in women. Specifically, the genotypes rs2073163-CC and rs1155974-TT, which were
associated with a higher risk of T2D and elevated serum acute phase reactant
concentrations in men, and with higher serum concentrations of MIF and CCL5 in
women, were linked with a higher prevalence of exudative AMD. We did not observe
any association with atrophic AMD, which was likely due to the small number of cases.
The same cytogenetic band, Xq22, has been linked to AMD previously by Zheng et al
(419), who  also observed gender-specific associations of the diaphanous 2 Drosophila
homologue- gene (DIAPH). However, DIAPH is located 3.5 Mb away from TNMD, and
there is practically no LD between the TNMD markers that were associated with AMD
and rs10521496 of DIAPH, which was associated with the risk of AMD in the previous
study (419). The pairwise r2 for rs10521496 and rs7890586 is 0.007, and for
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rs10521496 and rs2073163 or rs1155974 it is 0.1 in the CEU population of HapMap-
database (public release #26).
Abnormal neovascularization is an essential part of the pathophysiology of
exudative AMD, and genetic associations of angiogenesis regulators such as VEGF
(168-171) and PEDF (172,173) with AMD have been reported. In relation to these
previous association studies, the relationship between TNMD sequence variation and
exudative  AMD  raises  an  interesting  possibility  for  a  regulatory  role  of  TNMD  in
choroidal neovascularization and exudative AMD, but like other hypothetical
connections suggested in chapters 6.2.2-6.2.5, this will require replication in other study
populations and above all, functional studies. Interestingly, the ER chaperones (420)
and ER stress in general (421,422) are known to affect the expression of angiogenic
factors such as VEGF, and therefore TNMD could, in theory, affect the vascularization
via ER  stress  caused  by  the  dysfunction  of  the  BRICHOS-domain  and  the  resulting
accumulation of misfolded TNMD. Mutations in the BRICHOS-region of surfactant
protein C have been shown to increase ER stress via this mechanism (346).
In addition to angiogenesis, inflammation is involved in the pathogenesis of AMD
and the best established genetic risk factors are related to the complement system (145-
161,167,423-432). Thus, it might be that also these associations of TNMD could be due
to the association with the inflammatory status that was observed in DPS.
Unfortunately, there is no inflammatory marker data available from the AMD study
population.
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7 CONCLUSIONS
The sequence variation of TNMD was associated with glucose metabolism, serum
lipoprotein and inflammatory marker levels in men and with central obesity, serum
levels of systemic immune mediators and exudative AMD in women. All these
phenotypes are linked by inflammation and angiogenesis. As discussed in chapters
6.2.2-6.2.7, there are various parallels that provide an interesting basis for speculation.
The hypotheses depicting the mechanisms of the observed associations, based on the
available data from Studies I-IV are shown in Figure 9.
The effects of acute phase reactants and other inflammatory factors on lipolysis and
cholesterol synthesis are well recognized (263-265,433). It is also known that lipid
overload interferes with insulin signaling pathways, and that enhanced lipolysis and
dyslipidaemias contribute to the deterioration in glucose metabolism in obesity
(174,193,209,210). Therefore, it might be that the association of TNMD with
inflammation could explain many of the observed associations in men (Figure 9a). This
hypothesis is supported by the fact that the same genotype associated with elevated
serum concentrations of acute phase reactants in DPS, was related to elevated serum
LDL levels in obese individuals in DPS and METSIM, but controversially also to
increased HDL levels in the METSIM. In addition to this marker (rs2073162), two other
markers (rs2073163 and rs1155974) were associated with elevated serum
concentrations of CRP and SAA and elevated 2H-PG. In addition, these three markers
were associated with a higher risk of T2D in the DPS.
In  women,  the  same markers  that  were  associated  with  central  obesity  (rs4828037
and rs5966709) were associated with elevated serum concentrations of CCL3 and
CCL5. The sequence variation in the region of haploblock 2 was linked to
concentrations of CCL5 and MIF and two of these markers were associated with risk of
AMD. Therefore, one possible scheme is that the elevated serum levels of inflammatory
factors, secondary to central obesity, facilitate the pathophysiological changes related to
development of AMD (Figure 9b). In addition, due to its angiogenesis-inhibiting
properties, TNMD might also contribute to the altered neovascularization.
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Figure 9. Hypothesis for the putative mechanism for the observed associations of TNMD markers in a)
men and b) women. The events that were not measured in any of the study populations are indicated with
non-bolded cursive font. a) Acute phase reactants CRP and SAA can affect cholesterol metabolism and
SAA also promotes lipolysis. Altered lipoprotein metabolism and increased lipolysis disturb glucose
metabolism and thereby increase the risk of type 2 diabetes (T2D). b) Obesity, either general or central, is
associated with accumulation of macrophages in adipose tissue. These cells secrete proinflammatory
cytokines and other compounds, such as chemokine (C-C motif) ligands (CCLs) that further promote the
production of proinflammatory factors. Obesity and inflammation are related to vascular changes.
Inflammation and angiogenesis are essential in the pathogenesis of AMD, but obesity is also one of the
known risk factors.
7.1 Future implications
Since we performed only genetic association studies, it is difficult to suggest how
tenomodulin could participate in adiposity, glucose and lipid metabolism or
inflammation and therefore Studies I-IV generate new research hypotheses rather than
answering specific questions. The current published in vivo and in vitro studies with
TNMD do not provide explicit clues on the potential mechanisms. However, TNMD
shares interesting similarities with TSP-1. Both genes are expressed in adipose tissue
and the mRNA-levels correlate with obesity-related traits (286,325). The expression of
both genes is regulated via the extracellular-signal regulated kinase/mitogen-activated
protein kinase (ERK/MAPK)-signaling pathway (434-437) and high expression of both
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genes is associated with inflammation (438-440). The mRNA expression of these two
genes is also induced in the same phase during adipocyte differentiation (280,281).
Several adipokines, such as TSP-1 (286) and vaspin (382) have been identified by
investigating differences in mRNA expression in adipose tissue of obese and lean
subjects, and therefore it would be interesting to investigate if also TNMD could be an
adipokine. Our preliminary research has confirmed that TNMD is expressed in
adipocytes and blood vessels (Figure 8).
The  BRICHOS-domain  with  its  connection  to  ER  stress  and  the  C-terminal
angiogenesis-inhibiting domain provide interesting hypotheses for functional studies.
Since the TNMD-null mice were studied in the context other than obesity or T2D and
the mice did not harbour any drastic phenotypes in normal settings (345), the authors
did not conduct more detailed analyses. It would be interesting to investigate how the
TNMD-null mice would respond to a high-fat diet and to study the effect of TNMD
overexpression in a suitable model system on the phenotypes of interest. In addition, the
use of cell culture model systems might shed light on these putative connections.
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8 SUMMARY
These studies were carried out to examine the association between the variation in the
TNMD gene and obesity- and inflammation-related phenotypes. The conclusions from
the studies can be summarized as follows:
Study I: Three markers of the TNMD gene were associated with risk of T2D in men and
two other markers with central obesity in women during a follow-up of overweight
individuals with IGT. The association with T2D was not replicated in a cross-sectional
population-based sample. These discrepancies might be due to differences between
study populations or that different genes operate in distinct phases of T2D development.
Study II: The  markers  that  were  associated  with  the  risk  of  T2D  in  Study I, were
connected  to  the  serum  levels  of  CRP  and  SAA  in  overweight  men  with  IGT.
Furthermore, two of these markers were linked to the serum concentrations of sICAM.
The association was to some extent predictable, since the same genotypes which were
linked to a higher incidence of T2D had  higher serum levels of these inflammatory
markers. In addition, the association between TNMD sequence variation and serum
CCL5 concentrations was observed in men. In women, the genotypes that were
associated with central obesity were related to higher serum CCL3 levels. Furthermore,
an association with CCL5 and MIF was detected in women. These results suggest that
inflammation might be the link between TNMD, impaired glucose regulation and
obesity.
Study III: The same marker that was associated with T2D incidence and the
proinflammatory state was also associated with serum total and LDL-cholesterol in two
separate samples of Finnish men. These consistent, replicated findings further
strengthen the link between TNMD, metabolic syndrome and inflammation.
Study IV: Two markers that were associated with serum levels of MIF were related to
the higher prevalence of exudative AMD in women. This novel finding provides
another link to an obesity-related condition, which also has strong relationship to
angiogenesis and inflammation.
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